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ABSTRACT  
   
Patients with schizophrenia have impaired cognitive flexibility, as evidenced by 
behaviors of perseveration. Cognitive impairments may be due to dysregulation of 
glutamate and/or loss of neuronal plasticity in the medial prefrontal cortex (mPFC). The 
purpose of these studies was to examine the effects of mGluR5 positive allosteric 
modulators (PAMs) alone and in combination with the NMDAR antagonist MK-801, a 
pharmacological model of schizophrenia. An operant-based cognitive set-shifting task 
was utilized to assess cognitive flexibility, in vivo microdialysis procedures to measure 
extracellular glutamate levels in the mPFC, and diolistic labeling to assess the effects on 
dendritic spine density and morphology in the mPFC. Results revealed that chronic 
administration of the mGluR5 PAM CDPPB was able to significantly reduce the effects 
of chronically administered MK-801 on both behavioral perseveration and glutamate 
neurotransmission. Results also showed that CDPPB had no evidence of an effect on 
dendritic spine density or morphology, but the mGluR5 negative allosteric modulator 
fenobam caused significant increases in spine density and the frequency of occurrence of 
spines with smaller head diameters. Conclusions include that CDPPB is able to reverse 
MK-801 induced cognitive deficits as well as alterations in mPFC glutamate 
neurochemistry. The culmination of these studies add further support for targeting 
mGluR5 with PAMs as a novel mechanism to alleviate cognitive impairments in patients 
with schizophrenia. 
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CHAPTER 1 
INTRODUCTION 
Background and Significance 
Schizophrenia is a long term, progressive, and complex disease. Schizophrenia is 
comprised of several diverse symptoms that are generally grouped into two categories:  
positive symptoms and negative symptoms (Basso et al., 1998). Positive symptoms are 
termed to reflect the addition of behaviors to normal function, and negative symptoms are 
termed to reflect the loss of behaviors from normal function (Jackson, 1887). Positive 
symptoms are generally the most prominent behaviors as they typically initiate diagnosis 
and treatment as these symptoms are clear indicators of a severe psychotic disorder 
(Andreasen, 1995). Positive symptoms include disorders of perception (hallucinations, 
usually auditory in nature), inferential thinking (persistent delusions), disorganized 
speech and disordered thought pattern, as well as general bizarre and/or catatonic 
behaviors (Andreasen, 1995; Basso et al., 1998; Lewis & Lieberman, 2000). Negative 
symptoms are behaviors and subjective experiences that include alogia (lack of 
conceptual fluency and reduced speech output), affective blunting (lack of emotional 
expression), anhedonia (inability to experience pleasure), avolition (lack of motivation), 
as well as cognitive deficits that include impairments in sustained and span of attention, 
working/reference memory, and executive functions (Andreasen, 1995; Basso et al., 
1998; Lewis & Lieberman, 2000; Rowley et al., 2001). While each of these symptoms are 
present in some patients, each patient with schizophrenia has a different subset and 
degree of symptoms (Andreasen, 1995). 
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Cognitive impairments are clinically classified as a negative symptom, but are a 
core feature of schizophrenia that varies in degree of severity between affected 
individuals. Cognitive impairments can affect working memory, reference memory, 
attention, and executive functioning (Bora et al., 2010; Green et al., 2004; Keefe & 
Fenton, 2007). Impairments involving cognitive function can have profound effects on an 
individual’s quality of life, compromising their ability to maintain relationships, 
employment, or even appropriate daily hygiene practices (Ho et al., 2000; Ho et al., 1998; 
Silver et al., 2003). Additionally, primary symptoms of schizophrenia can facilitate 
secondary symptoms, such as depression (Glazer et al., 1981; Prusoff et al., 1979; Siris, 
1991). Afflicted individuals constitute 1/3 of the homeless population, and suicide rates 
are very high at roughly 10% (Inskip et al., 1998; Palmer et al., 2005; Regier et al., 1993; 
Rowley et al., 2001).  
Schizophrenia affects approximately 24 million (1.1%) people worldwide (Saha et 
al., 2005), and has an early age of onset that varies between gender and individual. 
Schizophrenia is a disease that affects young people and has a typical on-set in either 
their late teens or early twenties (Andreasen, 1995). The early onset contributes to 
schizophrenia being one of the most costly diseases since adequate treatment is necessary 
for the remainder of the person’s life (Andreasen, 1995; Messias et al., 2007). Total costs 
include drug treatment, residential accommodation, physician, and other healthcare 
services, which are estimated at $11.1 billion (Andreasen, 1995). In terms of lost 
productivity, additional costs to society are estimated at $20 billion (Andreasen, 1995; 
Knapp, 1997; Rowley et al., 2001).  
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The etiology of schizophrenia remains very difficult to determine, as ethnicity, 
geographic region, season of birth, and socioeconomic environment have not been useful 
predictors for this disease (Messias et al., 2007). However, there is a strong link between 
genetic factors and the development of schizophrenia. Studies involving monozygotic 
twins report a 70-80% concordance with schizophrenia (Cardno et al., 1999; Lichtenstein 
et al., 2009; Uher, 2014). These findings suggest that there is a genetic risk for 
schizophrenia, but that non-genetic factors, such as the environment and/or stress, play a 
role as well. 
 
Hypotheses for the Etiology of Schizophrenia 
 
Neurodevelopemental Hypothesis 
The neurodevelopmental hypothesis suggests that the pathophysiology of 
schizophrenia involves genetic factors, which begin before the brain approaches maturity. 
Subtle molecular abnormalities coupled with stressful environmental factors during 
critical developmental periods can lead to inefficient signaling in brain circuitries, which 
may cause the symptoms of schizophrenia (Brown et al., 2004; Fatemi et al., 2005; 
Krapelin, 1893). Keshavan’s “two-hit” model suggests that when insults occur during 
critical developmental periods, they can ultimately lead to brain maldevelopment and 
ultimately development of the disease. Critical developmental periods include early brain 
development, possibly during the second trimester and adolescence. During early brain 
development abnormal neuronal migration or connectivity may occur, and during 
adolescence excessive synaptic pruning may occur leading to loss of plasticity and proper 
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neural connectivity (Keshavan, 1999; Keshavan et al., 1999). Environmental factors 
linked to a higher concordance of schizophrenia may include prenatal viral or bacterial 
infections, obstetric complications, and other postnatal external stressors (Karlsson et al., 
2001; Lewis, 2001; Schmidt-Kastner et al., 2006).  
Magnetic resonance imaging (MRI) studies and post-mortem analyses support the 
neurodevelopmental hypothesis, reporting significant anatomical brain differences 
between schizophrenia patients and age-matched control subjects. Physiological 
differences that are present at the on-set of schizophrenia symptoms and progress slowly 
include: enlarged ventricles, decreased prefrontal cortical volume, decreased amygdala 
and hippocampal volumes, as well as deficits in gray matter volume in the left superior 
temporal gyrus, insular cortex, left medial temporal lobe, and ares of the prefrontal cortex 
(PFC) including the anterior cingulate and medial frontal gyri (Breier et al., 1992; 
Petronis et al., 1999; Sigmundsson et al., 2001).  
Given the executive control functions of the PFC over many aspects of cognition, 
the overall reduced cortical volume and activity, as well as retracted dendrites and 
dendritic spines observed in the PFC may be involved in the cognitive impairments 
associated with schizophrenia (Glantz & Lewis, 2000; Petronis et al., 1999). Dendritic 
spine density and morphology change due to processes such as learning and memory, and 
these changes are critical for maintaining proper synaptic functioning. Imaging studies in 
the rodent neocortex show that small spines predominantly contain N-methyl-D-aspartate 
(NMDA) type glutamate receptors and are highly plastic. In contrast, large spines 
predominantly contain α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) 
type glutamate receptors, and are highly stable (Bourne & Harris, 2007; Holtmaat et al., 
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2006; Kasai, 2006; Matsuzaki et al., 2001; Zui et al., 2005).  These observed differences 
have led to suggestions that small spines are required for learning new information, and 
stable spines may be required for proper functioning of circuits that underlie memory 
(Bourne & Harris, 2007; Kasai et al., 2003; Kasai et al., 2010). Thus, the loss of dendritic 
spine density and atrophy of existing dendritic spines in patients with schizophrenia may 
underlie impaired stability of synaptic function and lead to the observed cognitive 
impairments.   
Underlying processes for the neurodevelopmental hypothesis involve genes that may 
be involved in the risk of developing schizophrenia, known as susceptibility genes 
(Moises et al., 1995). The most prominent susceptibility genes include dysbindin 
(DTNBP1), neuregulin (NRG1) and disrupted in schizophrenia 1 and 2 (DISC1 and 
DISC2) (Le-Niculescu et al., 2007; Sullivan et al., 2006; Owen et al., 2005). These genes 
encode proteins that aid in regulating neuronal connectivity and synaptogenesis (Fatemi 
& Folsom, 2009). DISC1 may be partly responsible for the physical brain abnormalities, 
as its gene product modulates downstream proteins, which are responsible for neural 
migration and neural progenitor proliferation during embryonic brain development and in 
the adult hippocampus (Mao et al., 2009). Mutations in these genes are likely involved in 
the maldeveloped formation of specific neuronal pathways, involving glutamate and 
dopamine (DA), both of which have been suggested to be involved in schizophrenia-like 
symptoms (Stefansson et al., 2002; Stefansson et al., 2003; Liu et al., 2007). 
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Glutamate Hypothesis 
A second hypothesis for the etiology of schizophrenia evolved from case studies 
of individuals who exhibited psychotic symptoms similar to schizophrenia while under 
the influence of drugs such as phencyclidine (PCP) or ketamine (Allen & Young, 1978; 
Cohen et al., 1962; Javitt & Zukin, 1991; Krystal et al., 1994). PCP and drugs with a 
similar profile noncompetitively block N-methyl-D-aspartate (NMDA) type glutamate 
receptors and induce both positive and negative symptoms of schizophrenia, as well as 
cognitive impairments, resulting in a drug state that closely resembles schizophrenia. 
Specifically, the glutamate hypothesis proposes that the pathology of schizophrenia is due 
to hypofunctioning NMDA receptors (NMDAR) (Marek et al., 2010; Olney et al., 1999; 
Paz et al., 2008; Tsai & Coyle, 2002).  This hypothesis suggests that hypofunctional 
NMDAR, which are located on glutamatergic neurons and synapse onto DA neurons in 
the ventral tegmental area (VTA), are unable to excite those DA neurons. The lack of DA 
excitation may result in DA hypofrontality, and thus cause symptoms of cognitive 
impairments (Marek et al., 2010; Olney et al., 1999).  
The competing hyperglutamatergic “excitotoxicity” hypothesis (Gray & Roth, 
2007; Javitt, 2004) is based on the observation that NMDAR antagonists cause 
neurodegeneration of pyramidal neurons following acute and/or chronic administration 
(Gray & Roth, 2007; Javitt, 2004; Olney & Farber, 1995; Olney et al., 1999). This model 
suggests that the symptoms of schizophrenia may be due to NMDAR antagonist induced 
apoptotic changes, particularly in frontocingulate regions (Gray & Roth, 2007; Javitt, 
2004; Olney & Farber, 1995; Olney et al., 1999). Furthermore, hypofunctioning NMDAR 
may be due to compensatory mechanisms in response to previous chronic hyper-
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functioning glutamate signaling casuing excitotoxic neuronal cell death (Deutsch et al., 
2001; Javitt, 2004). In support of this hypothesis, NMDAR antagonists have been shown 
to increase extracellular glutamate levels in the mPFC and nucleus accumbens (NAC) 
(Adams & Moghaddam, 2001; Lena et al., 2006; Lopez-Gil et al., 2007, Lopez-Gil et al., 
2009; Lorrain et al., 2003; Moghaddam et al., 1997; Pietraszek et al., 2009; Roenker et 
al., 2011; Roenker et al., 2012; Zuo et al., 2006); and treatment naïve patients with 
schizophrenia were found to have significantly higher levels of glutamate in their 
cerebrospinal fluid (CSF) (Hashimoto et al., 2005). Lastly, memantine, a weak NMDAR 
antagonist, was shown to slow cognitive decline in advanced Alzheimer’s disease 
(Reisberg et al., 2003). This result suggests that excessive glutamate transmission 
contributes to neurodegeneration and cognitive decline in Alzhiemer’s disease, and thus 
possibly in schizophrenia as well.  
 
Dopamine Hypothesis 
The DA hypothesis suggests that hyperdopaminergic neurotransmission in the 
VTA results in the positive symptoms of schizophrenia. In a review of the dopamine 
hypothesis, Meltzer and Stahl (1976) suggest that schizophrenia symptoms are caused by 
excessive DA in the brain, particularly in the mesocorticolimbic DA pathway. This 
pathway begins in the VTA and projects to various regions in the limbic system and the 
prefrontal cortex (Meltzer & Stahl, 1976).   
The DA hypothesis originated from studies showing that antipsychotic drugs exert 
their effects by antagonizing D2-like receptors. Researchers provide evidence for this 
hypothesis by showing that antipsychotics inhibit the release of dopamine in rat striatal 
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slices (Seeman & Lee, 1975). This hypothesis gained support from many other studies 
that reported acute psychosis after amphetamine overdose, and produced behaviors 
indistinguishable from paranoid schizophrenia. Behaviors include disorder of thought, 
paranoid delusions, and auditory hallucinations (Beamish & Kiloh, 1960; Greenwood & 
Peachey, 1957; McConnell & Mcllwaine, 1961; O'Flanagan & Taylor, 1950). 
Amphetamine induces these symptoms by increasing the release of monoamines, and 
thus an overabundance of DA in the synapse.  
Revisions to the DA hypothesis add the possibility of an inverse relationship 
between excessive DA in the limbic system and diminished DA in the PFC. Therefore, 
revisions to the DA hypothesis offer a possible explanation for all primary symptoms 
associated with schizophrenia, rather than just the positive symptoms (Davis et al., 1991; 
Howes & Kapur, 2009). Decreased activity in the mesocortical DA pathway may lead to 
decreased DA in the PFC, which may underlie the cognitive and negative symptoms 
observed in schizophrenia patients (Brozoski et al., 1979; Davis et al., 1991; Goldman-
Rakic et al., 2004).Thus, it is suggested that there is an opposing relationship between 
these DA pathways, which include hyperdopaminergic activity in the mesolimbic 
pathway, and hypodopaminergic activity in the mesocortical pathway.  
 
Mesocorticolimbic Dopamine System 
 The mesolimibic and mesocoritcal DA pathways are critical for explaining the 
suggested physiology that may underlie the symptoms of schizophrenia. The glutamate 
and DA hypotheses for the etiology of schizophrenia are focused on dysfunctional 
neuronal signaling occurring within these pathways. The major components in the 
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mesocorticolimbic circuit are the PFC, amygdala, NAC, striatum and the VTA. The NAC 
is divided into the shell and the core. The shell sends efferent projections to several 
regions, including but not limited to, the ventromedial ventral pallidum, amygdala, 
preoptic area, hypothalamus, endopeduncular nucleus, and VTA (Ikemoto & Panksepp, 
1999). The core sends major efferent projections to several regions as well, which include 
the dorsolateral ventral pallidum, endopeduncular nucleus, lateral part of the VTA, and 
substantia nigra. The VTA receives afferent inputs from the PFC, NAC, BNST, lateral 
preoptic area, and lateral hypothalamus from frontal regions, and the superior colliculus, 
substantia nigra, dorsal raphé, parabrachial nucleus, and dentate nucleus of the 
cerebellum from brainstem regions. The NAC receives afferent inputs from frontal 
regions, which include the mPFC, amygdala, hippocampus, and thalamus, but also from 
the VTA, dorsal raphé, and mesopontine reticular formation (Ikemoto & Panksepp, 
1999). The PFC sends excitatory projections to the VTA that stimulate GABAergic 
interneurons and mesocortical dopamine neurons (Carr & Sesack, 2000). Infralimbic (IL) 
and prelimbic (PL) both project to the VTA (Vertes, 2004). PL projections extend to the 
NAC core and shell, but IL projections extend to the NAC shell (Vertes, 2004). The 
basolateral amygdala distributes excitatory projections to DA neurons in the midbrain 
and NAC (Cooper, 2002).  
 Dysfunctional excitatory projections in the mesocorticolimibic DA system may be 
responsible for the abnormal DA signaling that is suggested to explain the symptoms of 
schizophrenia. Thus, the mesocorticolimbic DA system provides a physical link between 
the glutamate hypothesis of schizophrenia and the DA hypotheses for schizophrenia. 
Stimulation of VTA DA neurons from PFC excitatory efferent projections is suggested to 
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be disrupted in patients with schizophrenia. Hypofunctioning NMDAR on VTA DA 
neurons cause decreased DA release in the mesocortical DA pathway, resulting in too 
little DA in the frontal cortex (Olney & Farber, 1995; Olney et al., 1999). At the same 
time, Hypofunctioning NMDAR on GABAergic interneurons are unable to inhibit DA 
release in the mesolimbic DA pathway and result in too much DA, thus providing an 
explanation for the suggested inverse relationship of the DA hypothesis of schizophrenia 
(Olney & Farber, 1995; Olney et al., 1999).  
 
Animal Models of Schizophrenia 
 Animal models of schizophrenia are essential for advancements in the production 
and screening of novel therapeutic compounds. However, developing a model that has 
construct, face, and predictive validity for a disease as complex as schizophrenia has 
proven difficult. Current models of schizophrenia can be classified into four main groups: 
pharmacological administration, developmental manipulation, genetic manipulation, and 
lesioning models. Each of these models has different strengths and weaknesses, and 
currently no animal model is able to adequately express all symptoms of schizophrenia. 
An appropriate model of schizophrenia should include face validity, expressing 
observable symptoms of schizophrenia. In animal models, positive symptoms are 
observed as hyperlocomotion and sensitization to stimulant effects, such as amphetamine. 
Negative symptoms are observed as social withdrawal and increased aggression. 
Cognitive impairments are observed as deficits in sensorimotor-gating (pre-pulse 
inhibition, PPI), as well as attention, working memory, and reference memory tests. 
Animal models should also include construct validity, which involves replicating the 
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theoretical pathophysiology of schizophrenia. Lastly, an adequate animal should also 
have predictive validity, which is demonstrated by the expected response to treatment by 
current antipsychotics (Jones, Watson, & Fone, 2011).  
 
Pharmacological Models of Schizophrenia 
The amphetamine model of schizophrenia is based on the DA hypothesis, and 
thus targets hyperactivity in the mesolimbic DA pathway. Amphetamine-induced 
psychosis produces positive symptoms that are very similar to schizophrenia, which 
include auditory hallucinations and persecutory delusions (Robinson & Becker, 1986). 
Chronic amphetamine administration in animals causes a robust model of the positive 
symptoms of schizophrenia, which are observed as hyperlocomotor activity and 
amphetamine sensitization (Featherstone et al., 2008; Robinson & Becker, 1986). 
However, neither acute nor chronic administration of amphetamine is able to induce the 
negative symptoms of schizophrenia (Featherstone et al., 2007; Javitt & Zukin, 1991). 
Amphetamine administration has been shown to cause long-lasting PPI deficits (Tenn et 
al., 2005; Peleg-Raibstein et al., 2006). Additonally, amphetamine sensitization was 
shown to impair attention and set-shifting ability, but not performance in spatial tasks 
(Featherstone et al., 2007; Fletcher et al., 2005). Pre-administration of clozapine or 
haloperidol demonstrated the ability to prevent amphetamine-induced sensitization 
(Martinez & Sarter, 2008; Meng et al., 1998). Thus, the amphetamine model induces 
psychotic like symptoms, but it is unable to replicate negative symptoms, or most 
cognitive impairments that are associated with schizophrenia. 
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 The phencyclidine (PCP) model of schizophrenia is based on the glutamate 
hypothesis of schizophrenia, and was formed by observing people under the influence of 
NMDA antagonists (i.e., PCP, ketamine or MK-801). These observations led to the 
suggestion that dysfunctional glutamate circuitries may be the primary mechanism 
mediating the pathophysiology of schizophrenia (Coyle et al., 2003; Konradi & Heckers, 
2003; Olney & Farber, 1995; Tsai & Coyle, 2002). In healthy subjects, administration of 
PCP induces psychosis, as indicated by delusions and hallucinations that are similarly 
observed as positive symptoms of schizophrenia (Cohen et al., 1962; Krystal et al., 1994). 
In schizophrenia patients, PCP can cause the onset or perpetuation of psychosis (Javitt & 
Zukin, 1991). Also in humans, acute and chronic PCP administration induces negative 
symptoms, such as social withdrawal and poverty of speech (Luby et al., 1959; Sams-
Dodd, 1996), as well as cognitive impairments. PCP induced symptoms are reversible 
with cessation of drug use (Cosgrove & Newell, 1991; Javitt & Zukin, 1991). In rodents, 
PCP administration causes hyperlocomotion (Kalinichev et al., 2008) social withdrawal 
(Sams-Dodd, 1995), PPI deficits (Mansbach & Geyer, 1989), as well as impairments in 
learning, attention, working memory and reference memory (Egerton et al., 2005; Jentsch 
et al., 1997; Marquis et al., 2007; Seillier & Giuffrida, 2009). The observed positive and 
negative symptoms are reversed by administration of both typical and atypical 
antipsychotics (Phillips et al., 2001; Sams-Dodd, 1998), but cognitive impairments are 
reversed only by atypical antipsychotics (Le Cozannet et al., 2010; Goetghebeur & Dias, 
2009). Chronic PCP administration results in neurochemical changes that are similar to 
those believed to underlie the pathophysiology of schizophrenia. This is supported by 
chronic PCP administration, which demonstrates that mesolimbic DA neurons are hyper-
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responsive to amphetamines and mild stress (Jentsch et al., 1998). Furthermore, chronic 
PCP administration results in reduced basal glutamate release in the PFC (Fattorini et al., 
2008), and increases PFC levels of the glutamate-aspartate transporter (GLAST), which 
suggests a mechanism for cortical glutamate hypofunction (Murai et al., 2007). Sub-
chronic PCP administration decreases dendritic spine density on cortical neurons (Flores 
et al., 2007), and reduces numbers of both cortical and hippocampal parvalbumin-
immunoreactive neurons (Abdul-Monim et al., 2007; Jenkins et al., 2008; Jenkins et al., 
2010; McKibben et al., 2010; Reynolds et al., 2004), which are also reflective of the 
pathophysiology observed in schizophrenia patients.  Overall, NMDAR antagonists 
display high face, predictive and construct validity, and thus adequately model 
schizophrenia symptoms in laboratory animals.  
 Although MK-801 and PCP share the same mechanism of action, and produce 
substantial overlap on behavioral effects, there are significant differences between the 
two. On the side of similarities, both drugs are NMDAR antagonists and have the same 
binding site on the receptor (Hirmatsu, Cho, & Nabeshima, 1989). Both stimulate ataxia, 
sniffing, locomotion, headweaving, turning, and backpedaling (Hirmatsu et al., 1989). 
Both are used as models of schizophrenia (Jones et al., 2011), and both stimulate DA 
turnover by releasing stored DA in vesicles, rather than releasing newly synthesized DA 
(Martin & Haubrick, 1985). Differences between MK-801 and PCP include binding 
specificity and potentcy. MK-801 has produced no evidence of effects on other receptor 
systems, with the exception of mediating the release of stored DA, which PCP also 
iniates (Nabeshima et al., 1983; Nabeshima et al., 1984). Alternatively, PCP has been 
shown to bind to other receptors, such as the sigma receptor, and is also potent 5-HT re-
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uptake inhibitor (Hirsch et al., 1997; Nabeshima et al., 1983; Nabeshima et al., 1984). 
MK-801 is indicated to be 20-40 times more potent than PCP (Hirmatsu et al., 1989). 
MK-801 induces dose-dependent behavioral effects (hyperactivity, ataxia, sniffing, ect.) 
at significantly lower doses than PCP (Hirmatsu et al., 1989). Also of notable importance, 
MK-801 has a much slower time course to reach maximum behavioral effects than PCP. 
MK-801 maximum effects occur between 30-45 minutes and PCP maximum effects 
occur between 0-15 mins (Himatsu et al., 1987; Nabeshima et al., 1986; Wong et al., 
1986).  
 
Neurodevelopmental Disruption Models of Schizophrenia 
 Neurodevelopmental models of schizophrenia are based on the 
neurodevelopmental hypothesis. This hypothesis suggests that a genetic predisposition 
and an early-life stressor can trigger maldevelopment of the brain, and possibly the onset 
of schizophrenia symptoms. Thus, developmental models utilize environmental 
manipulations and/or drug administration during critical developmental periods to cause 
changes in CNS development (Jones et al., 2011).   
 In one model, administration of the neurotoxin methylazoxymethanol acetate 
(MAM) administration on gestational day 17 (GD17) has been shown to cause 
hyperlocomotion, (Lodge & Grace, 2007), PPI deficits (Talamini et al., 2000), and 
impairments in reversal-learning and set-shifting tasks (Gourevitch et al., 2004; Le Pen et 
al., 2006; Moore et al., 2006). Only one study evaluated the effect of antipsychotics on 
MAM-induced impairments. This study showed that neither clozapine nor haloperidol 
were able to reverse any of the above mentioned impairments (Fiore et al., 2007). Subtle 
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physiological abnormalities that are similar to those observed in patients with 
schizophrenia have been observed in this model. These abnormalities include reductions 
in cortical thickness throughout the mPFC, hippocampus, and parahippocampal cortices, 
and disorientation of pyramidal neurons in the hippocampus (Flagstad et al., 2004; 
Kovelman et al., 1984; Le Pen et al., 2006; Moore et al., 2006). 
The post-weaning social isolation model utilizes social deprivation to alter brain 
development, and cause behavioral deficits that are evident in adulthood (Fone & 
Porkess, 2008; Lapiz et al., 2003). Rodents undergoing post-weaning isolation show 
locomotor hyperactivity (Dalley et al., 2002; Del Arco et al., 2004; Fone et al., 1996; 
Silva-Gomez et al., 2003), deficits in PPI (Bakshi et al., 1998; Cilia et al., 2001; Weiss et 
al., 1999) and impaired working memory, reference memory and cognitive flexibility 
(Dalley et al., 2002). Antipsychotics either fully or partially reverse the impairments that 
are observed as either positive or negative symptoms (Bakshi et al., 1998; Cilia et al., 
2001; Varty & Higgins, 1995; Wilkinson et al., 1994). Cognitive impairment reversal has 
been minimally examined, but chronic clozapine administration resulted in reduced 
impairment in a reversal learning task (Li et al., 2007). Neurochemical and structural 
changes observed in this model include increased DA in the mesolimbic pathway (Jones 
et al., 1992; Hall et al., 1998; Fone & Porkess, 2008), reduction in frontal cortical matter 
(Day-Wilson et al., 2006; Schubert et al., 2009), and reduced dendritic spine density and 
spine morphology (Silva-Gomez et al., 2003; Pascual & Zamora-Leon, 2006). 
 
Genetic Models of Schizophrenia 
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 Genetic models include knock-out (KO) or knock-down (KD) transgenic rodent 
strains in an effort to produce changes in mRNA and proteins in order to develop models 
of schizophrenia endophenotypes which may manifest underlying processes for specific 
susceptibility, or risk genes (Braff et al., 2007; Gottesman & Gould, 2003; O’Tuathaigh 
& Waddington, 2010). Of the many risk genes implicated in schizophrenia, some of the 
most prominent are DISC1, neuregulin and dysbindin.  
 DISC1 has long been thought to be involved in the pathophysiology of 
schizophrenia. DISC1 is a synaptic protein expressed early in development and exerts a 
prominent role in pre- and post-natal neuronal development.  DISC1 is particularly 
involved in synaptogenesis, neuronal migration and synaptic plasticity (Jaaro-Peled, 
2009), all of which are crucial for the proper physiological CNS structure. Some DISC1 
transgenic mice studies have reported hyperlocomotor activity (Clapcote et al., 2007), 
while other studies did not observe this (Koike et al., 2006; Li et al., 2007; Pletnikov et 
al., 2008). Social withdrawal was evident in some studies (Clapcote et al., 2007; 
Desbonnet et al., 2009; Li et al., 2007) whereas other studies did not observe this 
behavior (Hikida et al., 2007). Cognitive impairments observed in DISC1 mutant mice 
include deficits in PPI (Clapcote et al., 2007; Hikida et al., 2007), and working memory 
and executive function (Pletnikov et al., 2008). However, spatial tasks and novel object 
recognition are not affected (Arguello & Gogos, 2010; Hikida et al., 2007; Kvajo et al., 
2008). PPI deficits were reversed by haloperidol and clozapine (Clapcote et al., 2007; 
Hikida et al., 2007). Unfortunately no studies have examined the reversal of positive 
symptoms or cognitive impairments in DISC1 mice by administration of antipsychotics 
(Jones et al., 2011). DISC1 transgenic mice show physiological changes similar to those 
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observed in schizophrenia including enlarged lateral ventricles and reduced cortical 
thickness (Jaaro-Peled et al., 2010). In some but not all studies, DISC1 mutant mice 
demonstrate reduced parvalbumin immunoreactivity in the mPFC and hippocampus, 
which may underlie cognitive impairments (Clapcote et al., 2007; Hikida et al., 2007; 
Shen et al., 2008; Jaaro-Peled et al., 2010). Also, abnormal dendritic structure and density 
in the hippocampus have been observed in some DISC1 transgenic mice (Li et al., Li et 
al., 2007b; Kvajo et al., 2008). 
Neuregulin (NRG1) is involved in several crucial development functions such as 
synaptogenesis, neuronal migration, myelination, neuron glial interactions and formation 
of glial cells (Harrison & Law, 2006; Mei & Xiong, 2008; van den Buuse et al., 2009). 
Homozygous KO of NRG1 is fatal, however several viable heterozygous or 
hypomorphic/conditional KO mice have been developed and display schizophrenia-like 
symptoms (Harrison & Law, 2006a; Mei & Xiong, 2008). Between the many NRG1 
heterozygous or hypomorphic/conditional KO mice strains, there is a lot of symptom 
variability, but in general, NRG1 transgenic mice display hyperlocomotor activity in 
open-field and Y-maze tasks (O’Tuathaigh et al., 2007; Stefansson et al., 2002; van den 
Buuse et al., 2009), and abnormal socialization involving increased aggression and in 
some types social withdrawal (O’Tuathaigh et al., 2007; O’Tuathaigh et al., 2010). 
Cognitive impairments include PPI deficits (Stefansson et al., 2002), and impaired 
contextual fear conditioning (Arguello & Gogos, 2010; Ehrlichman et al., 2009), but 
working memory remained unaffected (O’Tuathaigh et al., 2007; O’tuathaigh et al., 
2010). Administration of clozapine was shown to reverse hyperlocomotion (O’Tuathaigh 
et al., 2007; Stefansson et al., 2002; van den Buuse et al., 2009). NRG1 transgenic mice 
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have increased parvalbumin-positive neurons in the mPFC and reduced levels of DA in 
the mPFC and hippocampus, none of which is similar to the suggested pathophysiology 
of schizophrenia (Kato et al., 2010). Overall, there is a profound lack of consistency of 
schizophrenia-like behaviors in NRG1 transgenic mice, and paired with a general lack of 
pharmacological studies, this model has very little face, predictive or construct validity.  
Dysbindin is a synaptic protein thought to regulate exocytosis, vesicle biogenesis 
and receptor trafficking in relation to excitatory neurotransmission (Karlsgodt et al., 
2011; Papaleo et al., 2010). Dysbindin mutations have high correlations with the risk and 
on-set of schizophrenia in humans, making dysbindin one of the most promising 
candidate risk genes (Allen et al., 2008; van den Buuse et al., 2009; Williams et al., 
2005). A naturally occurring mutation in mice [(named ‘sandy’ (sdy)] carries a 
homozygous, spontaneous deletion of exon 2 of the dysbindin gene, resulting in a 
naturally occurring loss of dysbindin (Papaleo et al., 2010). These dysbindin-lacking 
mice show hyperlocomotion (Cox et al., 2009; Papaleo et al., 2010; van den Buuse, 2010) 
and hypersensitivity to amphetamine-induced locomotion (Papaleo et al., 2010). Social 
withdrawal was reported in these mice (Papaleo et al., 2010), and cognitive impairments 
that have been observed include abnormal PPI responses (Feng et al., 2008; O’Tuathaigh 
et al., 2010), deficits in spatial reference memory and novel object recognition, but 
enhanced fear conditioning (Arguello & Gogos, 2010; Bhardwaj et al., 2009; Feng et al., 
2008; Takao et al., 2008). The increased PPI observed in these mice has been shown to 
be reversed by administration of quinpirole (Papaleo et al., 2010). Physiological 
alterations in dysbindin mutant mice include abnormal dendritic spine morphology in 
excitatory synapses in the hippocampal CA1 region, and reduced number of presynaptic 
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glutamate-containing vesicles (Chen et al., 2008; Feng et al., 2008; Jaaro-Peled et al., 
2010).  
 
Lesion Models of Schizophrenia 
In lesion models of schizophrenia, site-specific lesions produced on postnatal day 
7 by local injection of ibotenic acid into the ventral hippocampus (Becker et al., 1999; 
Lipska et al., 1993) cause behaviors similar to schizophrenia which do not appear until 
after puberty (Tseng et al., 2009). This model produces hyperlocomotor activity (Lipska 
et al., 1993) and hypersensitivity to DA agonists (Lipska & Weinberger, 1993). Deficits 
include social withdrawal and aggression (Sams-Dodd et al., 1997). Cognitive 
impairments include deficits in PPI (Le Pen et al., 2000), impaired spatial learning, and 
impaired working memory (Chambers et al., 1996). Both haloperidol (Sams-dodd et al., 
1997) and risperidone (Richtand et al., 2006) have been shown to reduce amphetamine 
induced hyperlocomotor activity in this model. However, clozapine was unable to reverse 
neither social withdrawal nor aggression (Sams-Dodd et al., 1997). In vivo microdialysis 
studies have shown DA levels to be unaltered in the nucleus accumbens in this model 
(Brake et al., 1999; Wan & Corbett, 1997), but reductions in dendritic spine density and 
dendritic length of pyramidal neurons in the mPFC and nucleus accumbens were 
observed (Flores et al., 2005; Marquis et al., 2008 
Antipsychotic Drugs 
 
Typical or First Generation Antipsychotics 
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Chlorpromazine was developed in 1950 as a pre-anesthetic drug, but it was 
observed to have a profound calming effect when administered to psychiatric patients. 
Chlorpromazine became the first line of treatment for psychosis (Meyer & Simpson, 
1997). In the following years several other drugs similar to chlorpromazine were 
developed, and these drugs became known as “typical” antipsychotics (APDs). Typical 
APDs reduce the positive symptoms of schizophrenia by acting as D2-like receptor 
antagonists and thus counteract the hypothesized hyperactive mesolimbic DA pathway. 
However, this same mechanism of action causes adverse side effects such as 
extrapyramidal side effects (EPS). EPS are a cluster of side effects that are Parkinsonian-
like state characterized by tremors, muscle rigidity, dystonia, and dyskinesia (Haro & 
Salvadr-Carulla, 2006; Owens, 1999). EPS is specifically caused by D2-like receptor 
inhibition in the nigrostriatal DA pathway which reduces DA transmission in the basal 
ganglia, causing motor disruption (Haro & Salvadr-Carulla, 2006; Owens, 1999). Also, 
D2-like receptor inhibition in the tuberoinfundibular DA pathway causes increased 
release of the hormone prolactin. Prolactin regulates reproductive functions, and an 
imbalance of this hormone can result in galactorrhea, amenorrhea and other possible 
sexual dysfunctions (Arana, 2000; Marken et al., 1992). 
 
 
 
Atypical or Second Generation Antipsychotics 
Clozapine was the first atypical or second generation antipsychotic to be 
developed (Hippius, 1999). Clozapine was considered atypical because it did not produce 
  21 
the expected side effects of typical antipsychotics such as EPS, prolactin elevation or 
catalepsy, which during that time were thought to be general properties of antipsychotic 
drugs. Atypical APDs are termed “atypical” due to the absence of the typical side effects, 
and have a different pharmacological profile. Atypical APDs target several binding sites, 
but have the highest affinity for the serotonin 5-HT2A receptor and relatively weaker 
affinity for dopamine D2-like receptors (Meltzer, Matsubara, & Lee, 1989). Atypical 
APDs lessen the risk for EPS and other side effects through the addition of 5-HT2A 
receptor antagonism and/or 5-HT1A agonism to their binding profile. Specifically, 5-HT2A 
antagonism and 5-HT1A agonism actually increase DA release just enough to reduce EPS, 
excessive prolactin release, and still alleviate positive symptoms (Kim et al., 2009; Stahl, 
2003). Atypical APDs may also lessen the risk of typical APD side effects by 
dissociating more quickly from receptors. This so-called ‘fast-off-D2’ or ‘rapid 
dissociation’ is based on the lower occupancy and affinity of atypical APDs for D2 
receptors, thereby lessening DA transmission enough to reduce positive symptoms, while 
maintaining enough  DA transmission to avoid related side effects (Seeman, 2002; 
Seeman, 2005; Stahl, 2003).      
Atypical APDs have complex mechanisms of action that have different affinities 
for different receptors that lead to varying effects on schizophrenia symptoms as well as 
varying side effects (Meyer & Simpson, 1997). Aside from targeting D2 and 5-HT2A 
receptors, atypical APDs also have effects on adrenergic, cholinergic, and histaminergic 
receptors (Schotte et al., 1996). The effects of targeting the aforementioned receptors 
cause adverse side effects including sedation, weight gain, dizziness and constipation 
among others (Fleischhaker et al., 2006; Hori et al., 2006; Lavalaye et al., 2001; 
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Lieberman, 2004; Raedler, 2007). Commonly prescribed atypical APDs include 
risperidone, olanzapine, ziprasidone, and quetiapine (Roth, Sheffler, & Kroeze, 2004).  
 
Third Generation Antipsychotics 
 A third class, or generation, of APDs has been recently developed. The prototype 
drug for this class is aripiprazole and has a different mechanistic profile than other 
atypical APDs. Aripiprazole and similar drugs such as bifeprunox have a greater affinity 
for DA receptors than other atypical antipsychotics, and instead of inhibiting D2-like 
receptors, these novel treatments act as partial agonists at D2-like receptors (Burris et al., 
2002). Because of this unique profile, both aripiprazole and bifeprunox have a lower 
propensity to elicit EPS despite their high affinity for DA receptors (Newman-Tancredi et 
al., 2007). Aripiprazole and bifebrunox bind to both D2 and D3 as well as 5-HT1A 
receptors (Ohlsen et al., 2005; Tadori et al., 2007; Tadori et al., 2008), and act to stabilize 
DA levels in the synapse, depending on the electrophysiological and biochemical state of 
the cell (Burris et al., 2002).    
Despite these pharmacological advancements, there is conflicting evidence for the 
efficacy of atypical APDs over typical APDs. Although several studies report that 
atypical APDs significantly benefit negative and cognitive impairments, other studies 
report either no improvements, or slight improvements, in negative and cognitive 
function over typical APDs (Geddes et al., 2000; Woodward et al., 2005). Meltzer and 
McGurk (1999) assessed how atypical antipsychotic drugs, clozapine, risperidone, and 
olanzapine affected various cognitive functions. Although it was found that the atypical 
APDs were able to improve some aspects of cognition, none showed improvements for 
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all cognitive domains. Risperidone improved working memory, executive function and 
attention (Green et al., 1997). Clozapine improved attention and verbal fluency, whereas 
olanzapine improved verbal learning and memory (Meltzer and McGurk, 1999; Silver et 
al., 2003). However, there have been discrepancies regarding the notion that atypical 
APDs benefit the negative and cognitive symptoms more so than typical APDs. Large 
scale studies such as the Clinical Antipsychotic Trials of Intervention Effectiveness 
(CATIE) and Cost Utility of the Latest Antipsychotic drugs (CUtLASS), have reported 
that atypical APDs were not necessarily superior over typical APDs. The most interesting 
result from both studies was the lack of significant differences found between typical 
APDs and atypical APDs efficacy for treating the negative symptoms and cognitive 
impairments (Jones et al., 2006; Lewis & Lieberman, 2008; Stroup et al., 2003). Thus, 
addition research and drug development are necessary to further improve the efficacy of 
current treatments for schizophrenia. 
 
The Glutamate System 
Glutamate is the most prevalent excitatory neurotransmitter in the central nervous 
system, mediating as much as 70% of both fast and slow excitatory neurotransmission 
(Olive, 2009). Glutamate receptors are either ligand-gated ion channels (i.e., ionotropic 
glutamate receptors, or iGluRs) or G-protein coupled receptors (i.e., metabotropic 
glutamate receptors, or mGluRs). iGluRs are ion channels that are permeable to cations 
and function by allowing Na
+
 and Ca
2+
 to enter the cell initiating action potentials and 
activating various intracellular signaling pathways. iGluRs are located on the head of 
postsynaptic dendritic spines, mediate fast excitatory neurotransmission, and are divided 
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into three different subtypes: N-methyl-D-aspartate (NMDA), α-amino-3-hydroxyl-5-
methyl-4-isoxazole-propionate (AMPA), and kainic acid (KA) (Olive, 2010). mGluRs are 
located on both presynaptic terminals and postsynaptic dendritic spines (Conn & Pin, 
1997; Hermans & Challiss, 2001; Pin & Duvoisin, 1995). mGluRs mediate slower, 
modulatory neurotransmission, and based on their intracellular signaling and 
pharmacological properties, are categorized into three families. Group I mGluRs consists 
of mGluR1 and mGluR5 receptors, Group II mGluRs consists of mGluR2 and mGluR3 
receptors, and Group III consists of mGluR4, mGluR6, mGluR7 and mGluR8 receptors 
(Olive, 2009).  
 
Group I mGluR Signaling Mechanisms 
Group I mGluRs primarily utilize Gq/G11 signaling mechanisms that activate 
phosopholipase C to form diacylglycerol (DAG) and inositol triphosphate (IP3). DAG 
activates protein kinase C (PKC), while IP3 exerts further downstream effects by binding 
to IP3 receptors on the endoplasmic reticulum releasing intracellular Ca
2+
 which in turn 
activates other intracellular messengers such as calcium/calmodulin-dependent kinase II 
(CaMKII). PKC exerts further downstream effects by phosphorylating CREB and other 
signaling molecules, which can eventually lead to altered gene transcription (Hermans & 
Challiss, 2001). Other intracellular signaling targets of Group I mGluRs include 
pathways involving Gi/o and Gs signaling, as well as the mitogen-activated protein 
kinase/extracellular signal-related kinase (MAPK/ERK) and mammalian target of 
rapamycin (mTOR)/p70 S6 kinase pathway, both of which are highly implicated in the 
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regulation of synaptic plasticity (Hou & Klann, 2004; Iacovelli et al., 2002; Li et al., 
2007; Page et al., 2006; Saugstad & Ingram, 2008). 
 
Group I mGluRs Link to NMDA Receptors  
Group I mGluRs, particularly mGluR5, are physically linked to NMDA receptors 
by various scaffolding proteins (such as Homer, Shank and GKAP) and positively 
modulate NMDA receptor function. Through its activation of PKC, mGluR5 activation 
also increases the phosphorylation of NMDA receptor subunits, thereby indirectly 
increasing the probability of NMDA receptor channel opening (Niswender & Conn, 
2010). Due to the postsynaptic localization of Group I mGluRs, these receptors primarily 
initiate and regulate long-term potentiation (LTP) and long-term depression (LTD) by 
postsynaptic mechanisms such as potentiation of NMDA receptor function (Anwyl, 1999; 
Bellone et al., 2008; Gladding et al., 2009). These structural and biochemical interactions 
allow for the stimulation of group I mGluRs to activate NMDA receptors with less risk of 
inducing excitotoxicity (Albensi, 2007; Hardingham & Bading, 2003). 
 
Positive Allosteric Modulation of mGluR5 Receptors: Pro-cognitive Effects 
Positive allosteric modulators (PAMs) are ligands that facilitate receptor 
functioning in the presence of glutamate binding to the orthosteric binding site. Thus, 
mGluR5 PAMs are more indirect routes for modulating NMDA receptor function that 
reduce the possibility of adverse side effects such as excitotoxicity. Several studies have 
examined the effects of the administration of mGluR5 PAMs on cognitive enhancing 
abilities in impaired and unimpaired cognitive states. For example, pharmacologically 
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induced cognitive deficits have been shown to be reversed by administration of mGluR5 
PAMs in several different paradigms, including operant set-shifting tasks (Darrah et al., 
2008; Gastambide et al., 2013; LaCrosse et al., 2014), spatial alteration tasks (Fowler et 
al., 2013; Stefani & Moghaddam, 2010), active allothetic place avoidance (Vales et al., 
2010), reversal digging paradigms (Gastambide, 2012), social novelty discrimination 
(Clifton et al., 2013), and novel object recognition (Horio et al., 2013; Reichel et al., 
2011). PAM of mGluR5 also reversed induced sucrose impairments (Vardigan et al., 
2010) and taste aversion and inhibitory avoidance tasks (Fowler et al., 2011). Notably, 
mGluR5 PAMs have also been shown to improve spatial and recognition memory 
abilities in unimpaired animals (Ayala et al., 2009; Balschun et al., 2006; Uslaner et al., 
2009; Xu et al., 2013). Operant set-shifting tasks are of particular importance for 
measuring cognitive functions that are PFC-dependent. Performance on operant based 
delayed match-to-sample (DMS) and delayed nonmatch-to-sample-tasks (DNMS) have 
been shown to be PFC-dependent tasks in several studies. Joel and colleagues (1997) 
found that mPFC lesions produced profound deficits in rodent performance on the 
DMS/DNMS task. Also, Sloan and colleagues (2006) showed that only rodents that 
received excitotoxic bilateral lesions to the mPFC, but not the hippocampus, exhibited 
significant impairments in delayed match-to-position (DMTP) water maze task. Rodents 
with hippocampal excitotoxic bilateral lesions performed no different than controls on 
this task, indicating that DMS/DNMS task are PFC-dependent tasks. Additionally, 
cognitive set-shifting such as DMS/DNMS is an executive function that involves 
attention, inhibition of response, working memory and planning/problem solving, all of 
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which have been associated with DLPFC (Duke & Kaszniak, 2000; Grafman & Litvan, 
1999; Stuss & Alexander, 2000). 
In contrast, various studies have shown that mGluR5 negative allosteric 
modulators (NAMs) impair cognitive function in otherwise unimpaired animals. For 
example, when administered systemically or via the intracerebroventricular route, 
mGluR5 NAMs can impair performance on spatial and working memory tasks (Balschun 
& Wetzel, 2002; Simonyi et al., 2010). Also, mGluR5 knockout (KO) mice show 
impaired performance in spatial memory tasks as well as acquisition and extinction of 
conditioned fear (Lu et al., 1997; Xu et al., 2009). However, not all studies have 
demonstrated cognitive deficits induced by mGluR5 NAMs (Petersen et al., 2002). 
mGluR5 NAMs have also been shown to improve aspects of cognitive impairment. 
Fragile X syndrome (FXS) is the most commonly inherited form of mental retardation 
(Gross et al., 2012). FXS is the result of either a deficiency or loss of function of the 
fragile X mental retardation 1 (FMR1) protein (McLennan et al., 2011).  In FXS patients, 
mGluR5 NAMs such as 1-(3-chlorophenyl)-3-(3-methyl-5-oxo-4 H-imidazol-2-yl)urea 
(fenobam) have been shown to improve cognitive impairments (Berry-Kravis et al., 
2009). 
Reviewing the above listed published literature, mGluR5 PAMs have been shown 
to reverse induced deficits (Horio et al., 2013; LaCrosse et al., 2014; Reichel et al., 2011; 
Vales et al., 2010), and in some cases to enhance performance in learning and memory 
tasks in unimpaired animals (Ayala et al., 2009; Balschun et al., 2006; Uslaner et al., 
2009; Xu et al., 2013). While in other cases mGluR5 PAMs have shown no evidence of 
cognitive performance enhancement, it is important to note that no evidence of 
  28 
impairment or potentiation of impairment has been reported (Darrah et al., 2008; Stefani 
& Moghaddam, 2010). Alternatively, mGluR5 NAMs have been shown to cause 
performance deficits in cognitive based tasks in otherwise unimpaired rodents (Balschun 
& Wetzel, 2002; Simonyi et al., 2010). 
 It may be possible that the pro-cognitive effects of mGluR5 PAMs are due to 
enhanced dendritic spine plasticity. As discussed above, mGluR5 PAMs have been 
shown to be particularly successful in reversing cognitive impairments in animal models 
of schizophrenia such as PCP and MK-801(Darrah et al., 2008; LaCrosse et al., 2014; 
Stefani & Moghaddam, 2010). Patients with schizophrenia have been shown to have 
decreased dendritic spine density and atrophied spine size in the dorsolateral prefrontal 
cortex (DLPFC) and temporal regions (Glantz & Lewis, 2000; Hirsch et al., 1997), which 
have also been shown to have significantly less activity in schizophrenia patients during 
cognitive tasks as compared to control subjects (Tan et al., 2007). Acute and subchronic 
administration of MK-801 and other NMDAR antagonists in rodents at different 
developmental periods produce significant reductions in spine density in the mPFC, 
hippocampus, and striatum (Bellinger et al., 2002; Ramsey et al., 2010; Wedzony et al., 
2005) Given that NMDAR antagonists model symptoms of schizophrenia, and also cause 
decreased dendritic spine density, this physiological effect may be an indicator of 
underlying mechanisms involved in impaired cognitive function in patients with 
schizophrenia. It is therefore possible that mGluR5 PAMs rescue observed behavioral 
cognitive deficits in models of schizophrenia by increasing dendritic spine plasticity.  
3-cyano-N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamide (CDPPB) is a PAM that 
acts on mGluR5, and may have potential as a cognitive enhancer that may be beneficial 
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for the treatment of cognitive deficits observed in schizophrenia patients. CDPPB binds 
within the seven transmembrane domain of the mGluR5 receptor and acts as a positive 
modulator that indirectly increases the receptor’s activity. Group I mGluRs, which 
include mGluR1 and mGluR5 receptors, are densely expressed in areas of the brain 
necessary for cognition, such as the PFC, striatum and hippocampus (Stefani & 
Moghaddam, 2010).  
Several studies have shown that CDPPB can rescue MK-801 induced cognitive 
deficits in behavioral tasks with efficacy similar to that of antipsychotics such as 
clozapine, which are known to have beneficial effects on the negative symptoms of 
schizophrenia. Stefani and Moghaddam (2010) found that CDPPB at doses of 10 mg/kg 
and 30 mg/kg were both able to attenuate MK-801 induced cognitive deficits in a T-maze 
set-shifting task. Vardigan and colleagues 2010 found that MK-801 decreased the 
rewarding properties of sucrose (demonstrated by a marked decrease in sucrose intake) 
but not water. Acute administration of CDPPB proved comparable to clozapine and D-
serine in attenuating the MK-801 induced deficit (Vardigan et al., 2010). CDPPB has also 
shown to attenuate amphetamine induced hyper-locomotion and sensorimotor gating 
abnormalities, both of which lend support for further testing of this drug as a novel 
therapeutic target (Kinney et al., 2005). Together, these studies suggest that mGluR5 
PAMs may be a promising new treatments for more complex cognitive deficits such as 
those associated with schizophrenia. 
 
Dissertation Rationale 
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The purpose of this dissertation is to test the hypothesis that the mGluR5 PAM 
CDPPB will ameliorate induced cognitive impairments in an animal model of 
schizophrenia, increase structural plasticity of neuronal dendritic spines, and reverse 
pharmacologically increased extracellular levels of glutamate in the mPFC. Experiment 1 
will assess the ability of CDPPB to reverse MK-801 induced perseverative responding in 
an operant set-shifting task employing delayed matching/non-matching-to-sample 
procedure. It is predicted that co-administration of CDPPB and MK-801 will decrease 
MK-801 induced perseverative responding, and that administration of CDPPB as a 30 
min pre-treatment to MK-801 will prevent perseverative responding. Experiment 2 will 
test the effects of CDPPB on extracellular glutamate levels in the mPFC in naive and 
MK-801 treated rodents using in vivo microdialysis procedures. It is predicted that MK-
801 administration will increase extracellular glutamate levels in the mPFC and that 
CDPPB will reverse that effect. Furthermore, it is predicted that administration of 
CDPPB alone will cause a decrease in levels of extracellular glutamate in the mPFC.  
Experiment 3 will measure the effects of CDPPB on the structural plasticity of neurons 
by quantifying dendritic spine density and morphology in the mPFC using diolistic 
labeling procedures. It is predicted that administration of CDPPB will increase dendritic 
spine density, length, head diameter, and overall volume in the mPFC.  
mGluR5 PAMs may be viable novel treatments for the cognitive impairments 
associated with schizophrenia. While mGluR5 PAMs have been tested in several studies 
assessing reversal of MK-801 induced deficits in cognitive function using operant 
paradigms (Darrah et al., 2008; Gastambide et al., 2013), no studies to date have 
examined the importance of pre-treatment and timing between mGluR5 PAM and MK-
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801 administration in these paradigms (Experiment 1). In addition, no studies to date 
have examined the effects of mGluR5 PAMs on extracellular glutamate levels 
(Experiment 2) or on dendritic spine morphology in the mPFC (Experiment 3), a region 
critically involved in various aspects of cognition.  It is our hope that the culmination of 
these studies lends further support to the notion that potentiation of mGluR5 function 
may be a novel therapeutic approach to improving cognitive function in neuropsychiatric 
diseases such as schizophrenia. 
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CHAPTER 2 
MGLUR5 POSITIVE ALLOSTERIC MODULATION AND ITS EFFECTS ON 
MK-801 INDUCED SET-SHIFTING IMPAIRMENTS IN A RAT OPERANT 
DELAYED MATCHING/NON-MATCHING-TO-SAMPLE TASK 
Abstract 
Rationale Positive allosteric modulators (PAMs) of type 5 metabotropic glutamate 
receptors (mGluR5) exert pro-cognitive effects in animal models of various 
neuropsychiatric diseases. However, few studies to date have examined ability of 
mGluR5 PAMs to reverse cognitive deficits in operant delayed matching/non-matching-
to-sample (DMS/DNMS) tasks. 
Objectives To determine the ability of the mGluR5 PAM 3-cyano-N-1,3-diphenyl-1H-
pyrazol-5-yl)benzamide (CDPPB) to reverse set-shifting deficits induced by the NMDA 
receptor antagonist MK-801. 
Methods Male Sprague-Dawley rats were initially trained to lever press for sucrose 
reinforcement under either DMS or DNMS conditions. Following successful acquisition 
of the task, reinforcement conditions were reversed (DNMSDMS or DMSDNMS). 
In Experiment 1, rats were treated daily prior to each session with either vehicle/vehicle, 
vehicle/MK-801 (0.06 mg/kg) simultaneously, CDPPB (20 mg/kg)/MK-801 
simultaneously, or CDPPB 30 min prior to MK-801. In Experiment 2, rats were treated 
with vehicle/vehicle, vehicle/MK-801, or CDPPB 30 min prior to MK-801 only prior to 
sessions that followed task reversal.  
Results In Experiment 1, no group differences in initial task acquisition were observed. 
Rats treated with vehicle/MK-801 showed significant set-shifting impairments following 
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task reversal, which were partially attenuated by simultaneous administration of 
CDPPB/MK-801, and completely precluded by administration of CDPPB 30 min prior to 
MK-801. In Experiment 2, MK-801 did not impair reversal learning and no other group 
differences were observed.  
Conclusions MK-801 induced deficits in operant set-shifting ability were prevented by 
pretreatment with CDPPB.  MK-801 did not produce deficits in initial task learning or 
when treatment was initiated following task reversal.  
 
Introduction 
Cognitive impairment is a core feature of many chronic illnesses such as 
schizophrenia, Huntington’s disease, Alzheimer’s disease, and drug addiction. Cognitive 
impairments can affect working memory, reference memory, attention, cognitive 
flexibility, and various other aspects of executive functioning (Green et al. 2004; Silver et 
al., 2003). Secondary effects of cognitive impairments can affect a patient’s ability to 
maintain relationships, employment, or appropriate daily hygiene practices, and often 
result in cognitive and behavioral perseveration. Although such impairments and 
perseveration occur across a range of neuropsychiatric diseases, the focus of the present 
study was to examine this phenomenon in the context of schizophrenia.  
Schizophrenia affects approximately 1% of the population and is typically 
diagnosed in males during their early 20s and in females during their later 20s. As a 
result, adequate treatment is necessary for the remainder of the affected individual’s life, 
making schizophrenia one of the most burdensome and costly neuropsychiatric diseases 
(Rowley et al., 2001). There are several hypotheses regarding the underlying 
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pathophysiology of schizophrenia, one of which is hypofunctioning of the N-methyl-D-
aspartate (NMDA) glutamate receptor subtype (Lin et al., 2012; Olney et al., 1999; 
Snyder & Gao, 2013). As a result, glutamate-based therapies are currently being explored 
for the treatment of schizophrenia (Snyder & Gao, 2013; Krystal et al., 2010; Nisewender 
& Conn, 2010; Menniti et al. 2013). Direct pharmacological targeting of the NMDA 
receptor via the orthosteric glutamate binding site is generally regarded as a nonviable 
approach since NMDA receptor agonists produce CNS hyperactivity, seizures, and 
excitotoxicity. An alternative to directly targeting the orthosteric glutamate binding site is 
to directly or indirectly target binding sites for obligatory endogenous co-agonists such as 
glycine and D-serine. For example, inhibition of glycine transporters such as GlyT1 
increases extracellular levels of glycine and thereby facilitates NMDA receptor activity 
(Vandenberg & Aubrey, 2001). Furthermore, various GlyT1 inhibitors have shown 
efficacy in improving cognitive impairments in schizophrenia (Javitt, 2012).  
A third possible approach to increase NMDA receptor function is via activation of 
type 5 metabotropic glutamate receptors (mGluR5). Facilitation of mGluR5 activity 
indirectly increases NMDA receptor function through structural and biochemical 
coupling of these two receptor subtypes. mGluR5 and NMDA receptors are structurally 
linked via proteins such as postsynaptic density 95 (PSD-95), Shank, and the Homer 
family of proteins. Localization of these two receptors in close proximity facilitates their 
bidirectional coupling via signaling intermediates such as phospholipase C and 
intracellular calcium (Gerber et al., 2007; Hermans & Challiss, 2001; Piers et al., 2012), 
which increases NMDA receptor activity including increased probability of receptor 
channel opening (Menniti et al., 2013; Niswender & Conn, 2010). Currently, the most 
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advantageous approach to increasing mGluR5 receptor function is via positive allosteric 
modulators (PAMs), which increase mGluR5 signaling only in the presence of 
endogenous glutamate. The use of orthosteric mGluR5 agonists has proved to be a less 
viable approach, since these ligands exhibit limited brain penetrance following systemic 
administration, poor selectivity for specific mGluR subtypes, and induce rapid 
desensitization of the receptor (Chen & Conn, 2008; Krystal et al., 2010; Menniti et al., 
2013; Niswender & Conn, 2010). 
Results from several studies indicate that the mGluR5 PAM 3-cyano-N-1,3-
diphenyl-1H-pyrazol-5-yl)benzamide (CDPPB) reverses experimentally induced 
cognitive impairments in animal models of schizophrenia. Stefani and Moghaddam 
(2010) found that CDPPB at doses of 10 and 30 mg/kg attenuated dizocilpine (MK-801) 
induced cognitive deficits in a T-maze based set-shifting task. Clifton and colleagues 
(2013) found that acute administration of CDPPB and the mGluR5 PAM ADX47273 
reversed phencyclidine (PCP) and MK-801 induced impairment in social novelty 
discrimination in adult rats, and when administered during adolescence reversed early 
postnatal MK-801 and PCP-induced impairments. Alternatively, Horio and colleagues 
(2013) showed that when PCP was administered chronically, acute administration of 
CDPPB was unable to attenuate deficits in novel object recognition in mice; however, 
subchronic (14 days) of administration of CDPPB was effective in rescuing such 
impairments. Uslaner and colleagues (2010) also showed that CDPPB was able to 
ameliorate MK-801 induced cognitive impairments in novel object recognition, and 
Vales and colleagues (2010) found that CDPPB was effective in attenuating MK-801 
induced impairments in active allothetic place avoidance.  
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To our knowledge, very few previous studies have examined the ability of 
mGluR5 PAMs to reverse pharmacologically induced cognitive deficits in an operant set-
shifting paradigm (Darrah et al., 2008; Gastembide et al., 2012; Gastembide et al., 2013; 
Gilmour et al., 2013), and only one utilized CDPPB (Darrah et al., 2008). This distinction 
is important as Gastembide and colleagues (2012, 2013) found that mGluR5 PAM 
LSN2463359 was unable to reverse PCP-induced impairments on cognitive flexibility, 
utilizing a delay component. Operant-based paradigms offer the advantage of modeling 
tasks used to assess cognitive flexibility and perseveration in humans, such as the 
Wisconsin Card Sorting Task (Franke et al., 1992; Goldberg et al., 1987; Joel et al., 1997; 
Silver et al., 2003). In a study by Darrah and colleagues (2008), rats were trained to 
respond for food reinforcement based on discrimination between two perceptual stimuli 
dimensions (spatial location of the nosepoke aperture and illumination of a stimulus 
light), and effects of CDPPB on MK-801 induced deficits in this task were examined. 
However, this study did not employ a delayed matching/non-matching-to-sample 
component, which increases working memory load and thus increases the difficulty of the 
task (Dudchenko, 2004, Dudchenko et al., 2013). In a study by Gilmour and colleagues 
(2013), rats were trained to respond for food in a delayed non-matching-to-position nose-
poke paradigm, and the efficacy of the novel mGluR5 PAMs LSN2463359 and 
LSN2814617 on reversal of set-shifting performance deficits induced by the competitive 
(closed channel) NMDA receptor antagonist SDZ 220,581 were assessed. However, in 
this latter study, the efficacy of these mGluR5 PAMs against the effects of more widely 
used non-competitive (open channel) NMDA antagonists such as MK-801 were not 
assessed. In addition, both of these studies utilized acute dosing procedures which can 
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lead to difficulty in interpretation of the potential antipsychotic and pro-cognitive effects 
of these ligands when administered daily in a clinical setting (Hagan & Jones, 2005; 
Varvel et al., 2002).   
Therefore, the purpose of the present study was to assess the ability of CDPPB to 
reverse MK-801 induced cognitive deficits in an operant set-shifting task incorporating 
delayed matching/non-matching-to-sample procedures (Experiment 1). Chronic drug 
administration was utilized in order to more closely resemble daily intake patterns that 
are generally required for therapeutic purposes in humans. However, to control for the 
possibility that daily administration of CDPPB and/or MK-801 during the first phase of 
testing might have carryover effects on performance following task reversal, separate 
groups of animals received drug administration only during the post-reversal phase of the 
procedures (Experiment 2). Finally, many of the aforementioned studies have assessed 
the ability of CDPPB to reverse MK-801 induced cognitive deficits utilizing vastly 
different drug administration paradigms, with some studies administering CDPPB prior 
to MK-801, some administering the two drugs simultaneously, and others administering 
MK-801 prior to CDPPB. Therefore, a tertiary purpose of the present study was to 
establish whether pretreatment with CDPPB prior to MK-801 would produce more robust 
effects on set-shifting ability deficits as compared to simultaneous administration.  
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Methods and Materials 
 
Subjects 
Subjects were male Sprague-Dawley rats (Harlan Laboratories, Livermore, CA) 
weighing 250-300 g upon arrival. Rats were pair-housed throughout the duration of the 
study. The vivarium was held at a temperature of 22±1C, and a 12 hour reversed 
light/dark cycle (lights off 7 am) was used. Animals had free access to water throughout 
the experiment except during behavioral testing. Rats were food restricted to 80% of their 
body weight by allowing them to free-feed for one hour after each daily session. Food 
restriction was necessary since it has previously been demonstrated that MK-801 
decreases the reinforcing properties of sucrose in free feeding animals (Vardigan et al., 
2010), which would adversely affect task performance in the present study. In addition, 
food reinforcement was not used since it has previously been demonstrated that MK-801 
can actually increase food intake and meal size under certain conditions (Burns & Ritter, 
1997; Gillespie et al., 2005; Treece et al., 2000), thus confounding the use of food as a 
reinforcer in during behavioral testing. Experimental group sample sizes were as follows: 
vehicle/vehicle (n=8), vehicle/MK-801 (n=6), CDPPB/MK-801 simultaneously (n=7), 
and CDPPB 30 min prior to MK-801 (n=9). Animals were maintained in accordance with 
the guidelines described in the Guide for the Care and Use of Laboratory Animals 
(National Research Council, 1996) and all procedures and facilities were approved by the 
Institutional Animal Care and Use Committee at Arizona State University.  
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Drug Treatment 
3-cyano-N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamide (CDPPB) was synthesized 
by Chemir Analytical Services (Maryland Heights, MO) according to published methods 
(Kinney et al., 2005) and suspended in a vehicle consisting of 10% v/v Tween 80 (Sigma-
Aldrich, St. Louis, MO). MK-801 was purchased from Sigma-Aldrich and dissolved in 
sterile saline (0.9% w/v NaCl). Doses for CDPPB (20 mg/kg) and MK-801 (0.06 mg/kg) 
were based on previous studies (Ayala et al., 2009; Horio et al., 2013; Stefani & 
Moghaddam, 2010; Uslaner et al., 2009) and pilot work performed in our laboratory. All 
drugs were administered via the subcutaneous (s.c.) route in a volume of 0.5 ml. 
 
Delayed Matching/Non-Matching-to-Sample Paradigm 
Delayed match-to-sample (DMS) or non-match-to-sample (DNMS) tasks were 
based on previously published procedures (Joel et al., 1997) and were conducted in daily 
sessions (approx. 45 min in length) consisting of 30 trials per session. Each trial was 
comprised of three components: a sample component, choice component and an inter-
trial interval (ITI). At the beginning of each daily session, animals were placed into 
standard operant conditioning chambers (model ENV-007, Med Associates, St. Albans, 
VT) containing a house light, food receptacle and two retractable levers. Each chamber 
was interfaced to a PC computer, and MED-PC IV software (Med Associates) was used 
to control experimental parameters and record responses. The house light was illuminated 
to signal the beginning of the first trial. During the sample component, either the left or 
right lever, designated the sample lever, was randomly inserted into the chamber. 
Pressing the sample lever resulted in delivery of a sucrose pellet reinforcer (45 mg, Test 
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Diet, St. Louis, MO) and a 30 sec delay. Following the delay, the choice component of 
the task commenced wherein both levers were inserted into the chamber. During the 
choice component, if the animal was assigned to the DMS condition as the initial task and 
pressed the same lever that was presented during the sample component, a sucrose pellet 
was delivered followed by a 30 sec inter-trial interval (ITI). An incorrect lever press 
resulted in the house-light turning off and initiation of a 60 sec time-out period. 
Alternatively, if the animal was assigned to the DNMS condition for the initial task and 
pressed the lever that was not presented during the sample component, a sucrose pellet 
was delivered followed by a 30 sec ITI. To control for task-specific learning, half of the 
subjects in each group were assigned to the DMS condition as the initial task and the 
other half the DNMS. Animals were considered to have met acquisition criteria when 
they exhibited at least 80% correct responses for 4 consecutive days, and were allowed a 
maximum of 21 days of testing to meet this criterion. In the event animals reached this 
criterion prior to 21 days of testing, they continued in the same testing conditions through 
the 21
st
 day of testing. Animals that did not reach the 80% correct acquisition criteria by 
the 21
st
 day of testing were removed from the study. On Day 22 of testing, animals were 
switched from their previously assigned task to the opposite task (i.e., DNMS→DMS, or 
DMS→DNMS) and subsequently tested for 21 additional days. Animals were then 
euthanized by anesthesia with isoflurane followed by decapitation and brain removal. 
 
Testing Procedures 
In Experiment 1, animals were randomly assigned to one of the following 4 
treatment groups and were treated 20 min prior to each daily session with the following 
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drug combinations: vehicle/vehicle, vehicle/MK-801 (0.06 mg/kg) simultaneously, 
CDPPB (20 mg/kg)/MK-801 simultaneously, or CDPPB 30 min prior to MK-801. In 
order to control for the possibility that daily administration of CDPPB and/or MK-801 
during the first phase of testing (prior to task reversal) might have carryover effects on 
performance following task reversal, Experiment 2 was conducted, in which separate 
groups of animals underwent similar initial testing, but received either vehicle/vehicle, 
vehicle/MK-801, or CDPPB 30 min prior to MK-801 only during the post-reversal phase 
of the procedures (days 22-42).  
 
Data Analyses 
For each daily session, the proportion of correct responses (calculated as the total 
number of correct responses divided by the overall total number of responses) were 
analyzed using a mixed two-way ANOVA with Treatment as the between-subjects factor 
and Day (session) as the within-subjects factor. Since initial analyses revealed no group 
differences during the acquisition of the initial task prior to task reversal for both 
Experiments 1 and 2, only data from sessions following task reversal were included in 
subsequent analyses. Multivariate ANOVAs were used to determine differences between 
specific treatment groups on each day of testing following task reversal. Statistical 
analyses were performed using Prism (version 5.00, GraphPad Software, La Jolla, CA) 
and SPSS (version 21.0, IBM, Armonk, NY). P-values less than 0.05 were considered 
statistically significant for all tests.  
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Results 
Each experimental group had an initial sample size of n=10 animals per group, 
half of which were initially assigned to the DMS condition and the other half to the 
DNMS condition. However, in Experiment 1, the following numbers of animals failed to 
meet acquisition criteria by the 21st day of the study, and were therefore removed from 
the experiment: vehicle/vehicle (n=2), vehicle/MK-801 (n=4), CDPPB/MK-801 
simultaneously (n=3), and CDPPB 30 min prior to MK-801 (n=1). Therefore, the final 
group sample sizes were as follows: vehicle/vehicle (n=8), vehicle/MK-801 (n=6), 
CDPPB/MK-801 simultaneously (n=7), and CDPPB 30 min prior to MK-801 (n=9). 
There were no apparent group biases in failure to acquire the task, such that roughly 
equal numbers of animals in each group acquired the initial DMS or DNMS task. In 
Experiment 2, all 10 animals per group reached acquisition criteria during the initial 
phase of the experiment. 
Data from all 4 treatment groups in Experiment 1 are shown in Fig. 1A. For ease 
of visualization of inter-group comparisons, data from various treatment groups in Fig. 
1A are re-plotted in Figs. 1B, 1C and 1D. No group differences were observed during the 
initial task acquisition (days 1-21) (all p-values >0.05). Following task reversal (days 22-
42), a mixed two-way ANOVA revealed significant effects of Treatment (F3,26=5.21, 
p<0.01), Day (F20,520=170.95, p<0.001) and a Treatment x Day interaction (F60,520=2.04, 
p<0.001). Post hoc analysis revealed that animals in the vehicle/MK-801 group exhibited 
a significant decrease in proportion of correct responding as compared with the 
vehicle/vehicle group on days 29-35, 37, and 39-41 (all p’s<0.05), indicating that MK-
801 induced a significant impairment in set-shifting ability (Fig. 1B). Animals pre-treated 
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with CDPPB  30 min prior to MK-801 (CDPPB 30 min/MK-801, Fig. 1C) showed a 
significantly increased proportion of correct responding as compared with animals treated 
with vehicle/MK-801 group on days 29-35, 37, and 39-41 (all p’s<0.05), indicating a 
reversal of MK-801 induced deficits. Furthermore, pre-treatment with CDPPB prior to 
MK-801 resulted in performance equivalent to vehicle/vehicle treated rats (all p’s >0.05, 
see Fig. 1D). However, simultaneous treatment with CDPPB and MK-801 produced only 
partial attenuation of MK-801 induced deficits in set-shifting ability, as compared to the 
vehicle/MK-801 group (Fig. 1E), as evidenced by a significantly increased proportion of 
correct responding only on day 33 (p<0.05), and a trend towards significant differences 
on days 31, 34, and 41 (p’s=0.08, 0.07, and 0.06, respectively).  
In Experiment 2, no group differences were observed in acquisition of the initial 
task (all p’s>0.05). Following task reversal (Fig. 1F), a mixed two-way ANOVA revealed 
a significant effect of Day (F20,567=70.87, p<0.001) but no significant effects of treatment 
(p>0.05) or a Treatment x Day interaction (p>0.05). These results suggest that MK-801 
does not induce impairments in set-shifting ability when treatment is initiated following 
task reversal, and that are no significant effects of CDPPB on set-shifting ability.  
 
Discussion 
In this study, we demonstrated that pharmacological blockade of NMDA 
receptors with MK-801 produced deficits in a delayed matching/non-matching-to-sample 
operant set-shifting task, and these effects were reversed when the mGluR5 PAM 
CDPPB was administered 30 minutes prior to, but not simultaneously with, MK-801. 
While other studies have reported similar positive effects of mGluR5 PAMs on the 
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reversal of deficits in operant set-shifting paradigms induced by NMDA receptor 
antagonists (Darrah et al., 2008; Gilmour et al., 2013), it should be emphasized that the 
current study, as well as that conducted by Gilmour and colleagues (2013), employed a 
delayed matching/non-matching-to-sample component, which increases working memory 
load and can be considered to be of increased translational value in the assessment of the 
efficacy of novel antipsychotic medications (Dudchenko, 2004; Dudchenko et al., 2013). 
In addition, most other studies (summarized below) examining mGluR5 PAM-induced 
reversal of the cognitive impairing effects of MK-801 have used either acute or 
subchronic dosing regimens, whereas in the present study animals received 
pharmacological treatments either throughout the course of the study (Experiment 1) or 
only during the post-reversal phase (Experiment 2). As suggested by others (Hagan & 
Jones, 2005; Varvel et al., 2002), we assert that chronic dosing regimens such as those 
used in the present study have a higher translational value for assessing the efficacy of 
novel cognition-enhancing or antipsychotic medications, which would most likely require 
daily dosing in humans.   
 The ability of CDPPB to reverse MK-801 induced deficits in set-shifting ability 
is consistent with other findings indicating reversal of pharmacologically induced 
cognitive effects of mGluR5 PAMs using non-delay based operant tasks (Darrah et al., 
2008); spatial alternation tasks (Fowler et al., 2013; Stefani & Moghaddam, 2010); social 
novelty discrimination (Clifton et al., 2013); novel object recognition (Horio et al., 2013; 
Reichel et al, 2011; Uslaner et al., 2009); and active allothetic place avoidance (Vales et 
al., 2009). mGluR5 PAMs have also been shown to reverse MK-801 induced 
impairments in sucrose preference (Vardigan et al., 2010), taste aversion and inhibitory 
  45 
avoidance tasks (Fowler et al., 2011), and alterations in prefrontal cortex neuronal firing 
patterns (Lecourtier et al., 2007; Homayoun et al., 2008; Homayoun & Moghaddam, 
2010). In unimpaired animals, mGluR5 PAMs have been shown to improve spatial and 
recognition memory abilities (Ayala et al., 2009; Balschun et al., 2006; Uslaner et al., 
2009). Thus, mGluR5 PAMs appear to be a promising class of cognition-enhancing 
agents, although recent reports of neurotoxicity induced by high dose exposure to these 
compounds requires further investigation (Parmentier-Batteur et al., 2013). 
The more robust efficacy of CDPPB pretreatment 30 min prior to MK-801 as 
compared with simultaneous administration of these two ligands is likely attributable to 
one or more factors. One possibility is that CDPPB may be slower to enter the brain than 
MK-801. In support of this, Kinney and colleagues (2005) demonstrated that acute 
CDPPB administration produces a brain-to-plasma area under the curve (AUC) ratio of 
1.7, while Vezzani and colleagues (1989) showed that MK-801 produces a brain-to-
plasma AUC of 12.5, suggesting significantly improved brain penetration of MK-801 vs. 
CDPPB.  Another possibility is that CDPPB is less able to reverse the cognitive effects of 
MK-801 when this latter ligand is already bound to the NMDA receptor. This latter 
possibility may seem unlikely in light of findings by Stefani and Moghaddam (2010), 
which showed that treatment of rodents with similar doses of MK-801 prior to CDPPB 
prevented MK-801 induced deficits on cognitive set-shifting ability in a spatial plus maze 
task. However, in this study, both drugs were administered acutely rather than chronically 
as in the present study, and thus the order of ligand administration may become more 
important when these ligands are given repeatedly. Another possible explanation for the 
  46 
improved efficacy of CDPPB, when administered 30 min prior to MK-801, as opposed to 
simultaneously may lie within the mechanism of action of MK-801.  
Worthy of discussion is the fact that recent findings suggest that there are 
different functional classes of mGluR5 PAMs that can exert differential effects on 
mGluR5 receptor function and the ability to reverse cognitive or behavioral deficits 
induced by NMDA receptor antagonists. For example, it has been reported that newer 
mGluR5 PAMs such as LSN2463359 and LSN2814617 are able to reverse decrements in 
instrumental responding for food as well as reversal learning in a digging-based and 
delayed match-to-position food seeking tasks induced by the competitive (closed 
channel) NMDA receptor antagonist SDZ 220,581 ( Gilmour et al., 2013). Surprisingly, 
LSN2463359 failed to reverse performance decrements in these tasks induced by the non-
competitive (open channel) NMDA receptor antagonists MK-801 and PCP (Gastambide 
et al., 2013). However, it should be noted that these studies only evaluated the acute 
effects of these mGluR5 PAMs. Ligand binding and pharmacokinetic experiments in 
these studies revealed very different profiles of these newer mGluR5 PAMs as compared 
to CDPPB, such that increased brain penetrance, receptor affinity, and binding to an 
allosteric site on the mGluR5 receptor are different from that of CDPPB. Importantly, it 
has been suggested that mGluR5 PAMs acting on separate allosteric binding sites on the 
receptor recruit different signal transduction mechanisms, with some allosteric sites 
inducing increased intracellular calcium mobilization as compared to activation of 
extracellular signal-related kinase 1/2 (ERK1/2), and vice versa (Zhang et al., 2005). 
These different binding profiles and subsequent engagement of different cellular 
signaling mechanisms may ultimately influence their ability to indirectly potentiate 
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NMDA receptor function when the receptor is in an open or closed state. Thus, the ability 
of mGluR5 PAMs to attenuate or reverse cognitive and behavioral impairments that are 
induced by NMDA receptor blockade may be highly dependent on the molecular profile 
of each ligand used, as well as the dosing regimen and behavioral paradigm employed. 
Future studies are necessary to determine the precise cellular signaling mechanisms 
underlying the effects observed in the present study. 
Finally, another finding from the present study is that MK-801 does not induce 
impairments in the acquisition of set-shifting ability when MK-801 treatment is initiated 
following task reversal. These observations are consistent with various bodies of 
literature suggesting that impaired NMDA receptor function at low to moderate doses 
does not lead to deficits in initial task learning (Chadman et al., 2006; Harder et al., 1998; 
Murray et al., 1995; Palencia & Ragozzino, 2004; van der Meulen et al., 2003; van der 
Staay et al., 2011; Wozniak et al., 1990), but appears to have more deleterious effects on 
set-shifting that result in behavioral and cognitive perseveration (Braff et al., 1991; 
Egerton et al., 2005; Franke et al., 1992; Goldberg et al., 1987; Green et al., 2004; Silver 
et al., 2003). However, it could be argued that in Experiment 1 of the present study, the 
behavioral effects of CDPPB and/or MK-801 following task reversal could have been a 
result of accumulation of either drug during chronic drug administration prior to task 
reversal. The plasma elimination half-lives of CDPPB in rats are approximately 4 and 2 
hrs, respectively (Kinney et al., 2005; Vezzani et al., 1989), and with chronic 
administration such an accumulation could indeed occur. However, several observations 
in the present study argue against this possibility. First, should any behavioral effects of 
CDPPB be carried over from the pre-reversal to the post-reversal phase, these effects 
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would likely have been observed in both the CDPPB/MK-801 and CDPPB 30 min/MK-
801. However, this is doubtful since Experiment 1 demonstrated a reversal of the effects 
of MK-801 only in animals receiving CDPPB 30 min prior to MK-801 (Fig. 1A and 1C). 
Also, initiation of all drug treatments following task reversal (Fig. 1F) did not produce 
any deficits in acquiring the new task, suggesting a lack of carryover effects of MK-801 
from the first phase of the experiment to the second phase. Finally, it has previously been 
demonstrated that long-term cognitive impairing effects by chronically administered MK-
801 are predominantly observed at high doses (i.e., 0.2 mg/kg; Li et al., 2011) and not at 
the dose used in the present study (0.06 mg/kg). Taken together, these observations 
suggest that the ability of MK-801 to induce deficits in set-shifting ability, and its 
reversal by pretreatment with CDPPB, are mediated by continued drug administration 
following task reversal.  
In summary, the present study lends further support to the notion that potentiation 
of mGluR5 function may be a novel therapeutic approach to improving cognitive deficits 
involving NMDA hypofunction, especially those involving higher working memory loads 
(Krystal et al., 2010; Niswender & Conn 2010; Menniti et al., 2013; Snyder & Gao, 
2013). Also, our findings support previous research showing that low to moderate doses 
of MK-801 selectively impair reversal learning and behavioral perseveration, but do not 
impair initial task learning. This is consistent with the clinical literature where studies 
have shown that patients with schizophrenia or otherwise impaired prefrontal function are 
able to learn an initial cognitive task, but set-shifting ability and perseveration following 
a change in response contingency requirements is dramatically impaired (Braff et al., 
1991; Egerton et al., 2005; Franke et al., 1992; Goldberg et al., 1987; Green et al., 2004; 
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Silver et al., 2003). The present study also identifies the necessity of pretreatment with an 
mGluR5 PAM prior to administration of a non-competitive NMDA antagonist under 
chronic dosing conditions. Future studies examining the precise cellular signaling 
mechanisms downstream of mGluR5 receptor potentiation in producing the pro-cognitive 
effects are needed. Additional studies are also needed to explore the ability of novel 
mGluR5 PAMs with improved brain penetrance and receptor affinity to reverse cognitive 
deficits induced by closed channel NMDA antagonists, as well as in other genetic or 
neurodevelopmental models of cognitive dysfunction. In addition, future studies should 
also employ additional behavioral paradigms that assess other cognitive domains such as 
spatial memory, attention, and sensorimotor gating. 
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CHAPTER 3 
MGLUR5 POSITIVE ALLOSTERIC MODULATION REVERSES MK-801 
INDUCED INCREASES IN EXTRACELLULAR GLUTAMATE LEVELS IN 
THE RAT MEDIAL PREFRONTAL CORTEX 
Abstract 
Rationale Positive allosteric modulators (PAMs) of type 5 metabotropic glutamate 
receptors (mGluR5) exert antipsychotic-like and pro-cognitive effects in animal models 
of schizophrenia and drug addiction, and can reverse cognitive deficits induced by 
NMDA receptor antagonists. However, it is currently unknown if mGluR5 PAMs can 
modulate NMDA receptor antagonist-induced alterations in extracellular glutamate levels 
in the medial prefrontal cortex (mPFC). 
Objectives To determine the ability of the mGluR5 PAM 3-cyano-N-1,3-diphenyl-1H-
pyrazol-5-yl)benzamide (CDPPB) to reduce elevated extracellular glutamate levels 
induced by the NMDA receptor antagonist dizocilpine (MK-801) in the mPFC. 
Methods Male Sprague-Dawley rats were treated for ten consecutive days with either 
CDPPB (20 mg/kg s.c.) alone or in combination with MK-801 (0.06 mg/kg s.c.), or their 
corresponding vehicles. On the final day of treatment, in vivo microdialysis was 
performed in the mPFC and samples were collected every 30 min for monitoring of 
extracellular glutamate levels.  
Results Compared to animals receiving only vehicle, administration of MK-801 
significantly increased extracellular levels of glutamate in the mPFC. This effect was not 
observed in animals that were co-administered with CDPPB. Administration of CDPPB 
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alone had no evidence of an effect on extracellular glutamate levels in the mPFC as 
compared to animals treated only with vehicle. 
Conclusions The mGluR5 PAM CDPPB reverses increases in extracellular glutamate in 
the mPFC induced by MK-801. These findings provide neurochemical support for the 
ability of mGluR5 PAMs to reverse NMDA antagonist-induced cognitive deficits, which 
may underlie the mechanisms of these ligands to produce pro-cognitive effects in 
disorders such as schizophrenia and drug addiction. 
 
Introduction 
Cognitive impairments are common in disorders such as schizophrenia and drug 
addiction, and can affect working memory, reference memory, attention, and executive 
functioning (Green et al., 2004; Kalivas & Volkow, 2005; Panenka et al., 2013; Silver et 
al., 2003; Stavro et al., 2013).  Phencyclidine (PCP) and drugs such as MK-801 
noncompetitively block N-methyl-D-aspartate (NMDA) type glutamate receptors and 
induce cognitive impairments closely resembling those observed in schizophrenia (Allen 
& Young, 1978; Javitt & Zukin, 1991; Krystal et al., 2003). Consequently, it is suggested 
that dysregulation of NMDA receptors (NMDARs) may be involved in the 
pathophysiology of schizophrenia (Coyle et al., 2012; Gilmour et al., 2012; Zhou & 
Sheng, 2013). Of the many glutamatergic theories of schizophrenia, the NMDAR 
hypofunction theory suggests that dysregulation of glutamate neurotransmission is caused 
by hypofunctional NMDAR on subcortical GABAergic interneurons which disinhibit 
cortical glutamatergic efferent pathways, resulting in a hyperglutamatergic state (Marek 
et al., 2010). In addition, NMDA antagonism is a mechanism of action of various drugs 
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of abuse including alcohol and dissociative hallucinogens (Lovinger et al., 1989; 
Vollenweider, 2001), and chronic intake of various drugs of abuse alters synaptic 
glutamate homeostasis, the expression and function of various glutamate receptors, and 
extracellular levels of glutamate in various brain regions (Gass & Olive, 2008; Kalivas, 
2009). 
Glutamate is the most prevalent excitatory neurotransmitter in the central nervous 
system, mediating as much as 70% of both fast and slow excitatory neurotransmission 
(Gass & Olive, 2008). Glutamate receptors are either ligand-gated ion channels (i.e., 
ionotropic glutamate receptors, or iGluRs) or G-protein coupled receptors (i.e., 
metabotropic glutamate receptors, or mGluRs). iGluRs are ion channels that are 
permeable to cations, and function by allowing Na
+
 and Ca
2+
 to enter the cell initiating 
action potentials and activating various intracellular signaling pathways. iGluRs are 
divided into three different subtypes, NMDA, α-amino-3-hydroxyl-5-methyl-4-isoxazole-
propionate (AMPA), and kainic acid (KA) (Gass & Olive, 2008). mGluRs mediate 
slower, modulatory neurotransmission, and based on their intracellular signaling and 
pharmacological properties, are categorized into three families. Group I mGluRs consist 
of mGluR1 and mGluR5 receptors, Group II mGluRs consist of mGluR2 and mGluR3 
receptors, and Group III consist of mGluR4, mGluR6, mGluR7 and mGluR8 receptors 
(Gass & Olive, 2008; Olive, 2009). For the purposes of the present study, we will focus 
our discussions on Group I mGluRs. 
Group I mGluRs primarily utilize Gq/11 signaling mechanisms which activate 
phospholipase C to form diacylglycerol (DAG) and inositol triphosphate (IP3). DAG 
activates protein kinase C (PKC), while IP3 exerts further downstream effects by binding 
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to IP3 receptors on the endoplasmic reticulum, releasing intracellular Ca
2+
 which in turn 
activates other intracellular messengers such as calcium/calmodulin-dependent kinase II 
(CaMKII). PKC exerts further downstream effects via phosphorylation of cAMP 
response element-binding protein (CREB) and other signaling molecules which can 
eventually lead to altered gene transcription (Hermans & Challiss, 2001). Group I 
mGluRs, particularly mGluR5, are physically linked to NMDARs by various scaffolding 
proteins (such as Homer, Shank and GKAP), and positively modulate NMDAR function. 
Through its activation of PKC, mGluR5 activation indirectly increases the 
phosphorylation of NMDAR subunits, thereby indirectly increasing the probability of 
NMDAR channel opening (Niswender & Conn, 2010). Due to the postsynaptic 
localization of Group I mGluRs, these receptors can initiate and regulate long-term 
potentiation (LTP) and long-term depression (LTD) by postsynaptic mechanisms such as 
potentiation of NMDAR function (Anwyl, 1999; Bellone et al., 2008; Gladding et al., 
2009). These structural and biochemical interactions allow for the indirect activation of 
NMDARs while reducing the incidence of excitotoxicity (Albensi, 2007; Hardingham & 
Bading, 2003). 
Positive allosteric modulators (PAMs) of glutamate receptors are ligands that 
facilitate receptor functioning in the presence of endogenous glutamate binding to the 
orthosteric binding site. Various studies have demonstrated that mGluR5 PAMs such as 3-
cyano-N-1,3-diphenyl-1H-pyrazol-5-yl)benzamide (CDPPB) reverse cognitive 
impairments induced by NMDA antagonists. For example, Stefani and Moghaddam 
(2010) found that CDPPB at doses of 10 and 30 mg/kg attenuated MK-801 induced 
cognitive deficits in a T-maze based set-shifting task. Alternatively, Horio and colleagues 
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(2013) showed that when PCP was administered chronically, acute administration of 
CDPPB was unable to attenuate deficits in novel object recognition in mice; however, 
subchronic (14 days) of administration of CDPPB was effective in rescuing such 
impairments. Uslaner and colleagues (2009) also showed that CDPPB ameliorated MK-
801 induced impairments in a novel object recognition task. Other studies have 
demonstrated the ability of mGluR5 PAMs to reverse pharmacologically induced 
cognitive deficits in an operant set-shifting paradigm (Darrah et al., 2008; Gilmour et al., 
2013; LaCrosse et al., 2014). Finally, our laboratory has shown that mGluR5 PAMs have 
pro-cognitive effects of in animal models of addiction, such as facilitation of extinction 
learning (Cleva et al., 2011; Kufahl et al., 2013; Gass et al., 2014), which are mediated at 
least in part by sub-cortical regions of the mPFC (Gass et al., 2014), and reversal of 
methamphetamine-induced deficits in object recognition (Reichel et al., 2011). 
Various in vivo microdialysis studies have shown that administration of MK-801 
or other NMDA antagonists increases extracellular levels of glutamate in the mPFC, and 
these effects can be reversed by traditional antipsychotics (Adams & Moghaddam, 2001; 
Lena et al., 2006; Lopez-Gil et al., 2007, 2009; Lorrain et al., 2003; Moghaddam et al., 
1997; Pietraszek et al., 2009; Roenker et al., 2011; Roenker et al., 2012; Zuo et al., 2006). 
However, studies examining the effects of mGluR5 PAMs on extracellular 
neurotransmitter levels are very sparse, and of the few that have been published, they 
have generally focused on changes in extracellular levels of dopamine (Liu et al., 2008; 
Lecourtier et al., 2007). Given that mGluR5 PAM reverse MK-801 and other 
pharmacologically induced cognitive deficits, and the effects of mGluR5 PAMs on 
extracellular glutamate levels are largely unknown, the purpose of this study was to 
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examine the effects of the mGluR5 PAM CDPPB on extracellular glutamate levels in the 
mPFC in naive and MK-801 treated rodents.  
 
Methods and Materials 
 
Subjects 
Subjects were male Sprague-Dawley rats (Harlan Laboratories, Livermore, CA) 
weighing 250-300 g upon arrival. Rats were pair-housed until surgical procedures, after 
which they were single housed for the duration of the study. The colony room was held at 
a temperature of 22±1C, and a 12 hour reversed light/dark cycle (lights off 7 am) was 
used. Food and water were available to the animals ad libitum throughout the experiment. 
Animals were maintained in accordance with the guidelines described in the Guide for 
the Care and Use of Laboratory Animals (National Research Council, 1996) and all 
procedures and facilities were approved by the Institutional Animal Care and Use 
Committee at Arizona State University. 
 
Surgery 
For stereotaxic implantation of guide cannula, rats were anesthetized with 
isoflurane (2%) at a flow rate of 2 L/min. After anesthesia was obtained, rats were 
mounted in a stereotaxic frame (Stoelting, Wood Dale, IL), and the incisor bar was set at 
3.0 mm. A stainless guide cannula (21-gauge, Synaptech, Marquette, MI) equipped with 
dummy probe was unilaterally aimed at the medial PFC (anterior +3.2, lateral +0.6, and 
vertical – 2.2 mm relative to bregma and skull surface; Paxinos & Watson, 2007). 
  56 
Cannulae were secured to the skull with stainless steel skull screws and cranioplastic 
cement, and animals were allowed to recover for at least 2 days prior to commencement 
of drug treatment.  
 
Drug Treatments 
The mGluR5 positive allosteric modulator 3-cyano-N-(1,3-diphenyl-1H-pyrazol-
5-yl)benzamide (CDPPB) was synthesized by Chemir Analytical Services (Maryland 
Heights, MO). CDPPB was dissolved in 10% v/v Tween 80 (Sigma-Aldrich, St. Louis, 
MO) and administered at a dose of 20 mg/kg, and MK-801 (Sigma-Aldrich) was 
dissolved in saline and administered at a dose of 0.06 mg/kg. All rats received daily 
injections of CDPPB and/or MK-801 or their corresponding vehicles via the 
subcutaneous (s.c.) route in a volume of 0.5 mL for ten consecutive days. Animals were 
divided into 4 treatment groups and were treated for 10 days with the following drug 
combinations: vehicle/vehicle, vehicle/CDPPB, CDPPB/MK-801, and vehicle/MK-801. 
The first injection (CDPPB or vehicle) was given 30 min prior to the second injection 
(MK-801 or saline). Doses of CDPPB and MK-801 were chosen based on previous 
studies by our laboratory and others (Stefani & Moghaddam, 2010; Kufahl et al., 2013). 
 
Microdialysis Procedures 
On the 9
th
 day of drug treatment, animals were lightly anesthetized with 
isoflurane, dummy probes removed, and microdialysis probes equipped with 2 mm 
cuprophane membranes (20 kDa cut-off weight, outer diameter 0.36 mm, Synaptech) 
were implanted into the mPFC. Rats were then housed overnight in cylindrical 
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microdialysis cages equipped with dual channel liquid swivels mounted onto 
counterbalanced lever arms (Instech Laboratories, Plymouth Meeting, PA). Animals were 
provided with food and a water bottle. Probes were perfused overnight with artificial 
cerebrospinal fluid (aCSF) containing (125 mM NaCl, 2.5 mM KCL, 0.5 mM 
NaH2PO4H2O, 5 mM Na2HPO4, 1 mM MgCl2●6H2O, 5 mM D-glucose, 1.2 mM 
CaCl2●2H2O, pH-7.3-7.5) at a flow rate of 0.05 l/min. The following morning, the flow 
rate was increased to 1.5 l/min and samples were collected every 30 min. After 
collection of 4 baseline samples, the final pretreatment of CDPPB or vehicle injection 
was given, followed 30 min later by MK-801 or vehicle. A total of 5 post-injection 
samples were collected. At the end of sample collection, rats were deeply anesthetized 
with isoflurane and euthanized by decapitation. Brains were extracted, cut on a cryostat, 
stained with cresyl violet, and verified for correct microdialysis probe placement.  
 
HPLC Analysis of Glutamate Levels 
 Glutamate was quantified in dialysate samples using isocratic high-performance 
liquid chromatography with fluorescence detection. Samples were stored in the cooling 
tray (8°C) of a Shimadzu SIL-10AF autosampler and derivatized in a 3 min reaction with 
the addition of 30 μl of a solution containing o-phthaldehyde (10 mg %; dissolved first in 
1 ml 100% methanol and added to 29 ml of OPA Diluent (Pickering Laboratories, 
Mountain View, CA)) and mixed with 100% β-mercaptoethanol in a 1:2000 ratio. 
Sample separation was accomplished using an ESA HR-80 × 3.2 column with 120 m 
pore size (ESA, Chelmsford, MA). The mobile phase was 0.1 M dibasic sodium 
phosphate (pH 6.75) mixed with 28% methanol and continuously pumped at 0.5 ml/min 
  58 
using a Shimadzu LC-20AD Prominence pump. A Shimadzu RF-10XL Fluorescence 
Detector was set with an excitation wavelength of 348 nm and an emission wavelength of 
450 nm. Glutamate concentrations were determined against external standards using peak 
heights determined by LabSolutions Software (Shimadzu, LC solution Version 1.22 
SP1). The limit of detection for this assay was ~25 nM and the limit of quantification was 
~135 nM. 
 
Data Analyses  
For assessment of baseline differences in dialysate glutamate content, the average 
dialysate glutamate levels in the 4 baseline samples were compared across treatment 
groups using a one-way ANOVA. For the purposes of visualization of time course of 
drug effects, all glutamate values were converted to a percent baseline using the 
calculated raw baseline values for each rat.  For assessment of drug effects, raw dialysate 
glutamate content was converted to area under the curve (AUC) for the 5 post-injection 
samples (Gardier, 2013; Maskos et al., 2005; Mitsushima et al., 2013). For each animal, 
post-injection AUC values were calculated via trapezoidal approximation as AUC = 
0.5(C1+C2)(t2-t1) + 0.5(C2+C3)(t3-t2) + 0.5(C3+C4)(t4-t3)…., where CX is the dialysate 
glutamate concentration (C, in nM) in post-injection sample X, and tX is the time (in min) 
at the beginning of post-injection sample X. Time of injection was considered t=0. A one-
way ANOVA was used to determine overall group differences followed by post-hoc 
Newman-Keuls multiple comparison rests. Statistical analyses were performed using 
GraphPad Prism (version 5.00, GraphPad Software, La Jolla, CA). 
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Results 
Each experimental group had an initial sample size of n=10 animals per group. 
However, due to improper probe placement or microdialysis probe patency issues during 
sample collection, the following numbers of animals were removed from the experiment: 
vehicle/vehicle (n=3), CDPPB/vehicle (n=2), CDPPB/MK-801 (n=4), and vehicle/MK-
801 (n=4). Therefore, the final groups sample sizes were as follows: vehicle/vehicle 
(n=7), CDPPB/vehicle (n=8), CDPPB/MK-801 (n=6), and vehicle/MK-801 (n=6). The 
shaded area in Figure 2A indicates the region of the mPFC that was defined for proper 
placement of microdialysis probes.   
Figure 2B shows the time course of drug effects in all four treatment groups, 
expressed as a percent of baseline levels of glutamate. As shown in Figure 2C, no 
significant differences were observed in AUC values for baseline (samples 1-4) between 
treatment groups (F(3,23)=2.406, p>0.05).  Analyses of post-injection AUC values 
(samples 5-9, Figure 2D) revealed a significant effect of treatment group (F(3,23)=7.282, 
p<0.005). Post hoc analyses revealed that post-injection AUC values were significantly 
elevated in the vehicle/MK-801 group as compared to the vehicle/vehicle group (p<0.01), 
indicating that MK-801 produced an elevation in extracellular levels of glutamate in the 
mPFC. Post-injection AUC values in the CDPPB/MK-801 group were significantly lower 
than those in the vehicle/MK-801 (p<0.05), indicating a reversal of MK-801 induced 
increases in extracellular glutamate by pretreatment with CDPPB. These observations 
were further supported by a lack of significant differences in post-injection AUC values 
between the vehicle/vehicle and CDPPB/MK801 groups (p>0.05). Post-injection AUC 
values were not significantly different between the vehicle/vehicle and CDPPB/vehicle 
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groups, suggesting that administration of CDPPB alone does not alter extracellular levels 
of glutamate in the mPFC. 
 
Discussion 
 The primary findings of this study were that pretreatment with CDPPB 
significantly attenuated MK-801 induced increases in extracellular glutamate in the 
mPFC. However, administration of CDPPB alone showed no evidence of an effect on 
extracellular glutamate levels. Given that CDPPB and other mGluR5 PAMs have been 
shown to reverse pharmacologically induced performance deficits in prefrontal-mediated 
cognitive tasks such as set-shifting (Stefani & Moghaddam, 2010; Gilmour et al., 2013; 
Horio et al., 2013; Darrah et al., 2008; LaCrosse et al., 2014), our findings may provide a 
potential neurochemical correlate of the pro-cognitive effects of mGluR5 PAMs. These 
findings are consistent with those from electrophysiological studies, where it has been 
demonstrated that CDPPB prevents MK801-induced increases in spontaneous activity of 
pyramidal neurons in the mPFC, and also normalizes MK-801 induced disruption in burst 
activity of these neurons (Lecourtier et al., 2007). Thus, positive allosteric modulation of 
mGluR5 function may be a mechanism by which to restore disrupted excitatory 
neurotransmission in the mPFC that is observed in neuropsychiatric disorders such as 
schizophrenia and drug addiction. 
 In our study, we utilized a chronic (10 day) treatment regimen to more closely 
model typical daily dosing patterns in humans. We found no significant differences in 
basal levels of extracellular glutamate levels across all four treatment groups. This was 
somewhat surprising given the fact that acute treatment with MK-801 or NMDA 
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antagonists have been shown to increase extracellular glutamate levels in the mPFC 
(Adams & Moghaddam, 2001; Lena et al., 2006; Lopez-Gil et al., 2007, Lopez-Gil et al., 
2009; Lorrain et al., 2003; Moghaddam et al., 1997; Pietraszek et al., 2009; Roenker et 
al., 2011; Roenker et al., 2012; Zuo et al., 2006), and we expected to observe higher basal 
levels of extracellular glutamate in the vehicle/MK-801 group as compared to the 
vehicle/vehicle group. Alternatively, Zuo and colleagues (2006) demonstrated that 
repeated administration of MK-801 (7 days) actually reduced extracellular levels of 
glutamate in the mPFC, while acute MK-801 administration increased extracellular 
glutamate levels. However, it should be noted that this study used a much higher dose of 
MK-801 (0.6 mg/kg), therefore it is possible that repeated administration of the lower 
dose used in the present study (0.06 mg/kg) did not lead to the same neuronal adaptations 
that alter the directionality of MK-801 induced changes in  extracellular glutamate levels 
in the mPFC. In addition, baseline samples were collected in the morning following the 
9
th
 injection and prior to the 10
th
 injection, and thus any MK-801 induced increases that 
may have occurred on day 9 would likely have dissipated by the time baseline samples 
were collected. Regardless, the observed MK-801 induced increase in extracellular 
glutamate levels on day 10 are consistent with numerous other reports showing similar 
increases following acute administration (Adams & Moghaddam, 2001; Lena et al., 2006; 
Lopez-Gil et al., 2007, 2009; Lorrain et al., 2003; Moghaddam et al., 1997; Pietraszek et 
al., 2009; Roenker et al., 2011; Roenker et al., 2012; Zuo et al., 2006).  
 We also found no significant differences in baseline or post-injection levels of 
glutamate between animals treated with CDPPB alone and those treated with vehicle 
alone. Since the effects of CDPPB on extracellular glutamate levels have been largely 
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unexamined, future studies employing other doses of CDPPB, as well as longer or shorter 
treatment regimens are necessary to further confirm this lack of effect. Other studies have 
reported that activation of mGluR5 receptors with orthosteric agonists can increase basal 
or evoked glutamate release from the forebrain and other brain regions (de Novellis et al., 
2003; Fazal et al., 2003; Thomas et al., 2000; Pintor et al., 2000; Reid et al., 1999). 
Furthermore, the slower modulatory effects of mGluR5 PAMs and their allosteric mode 
of action may contribute to the observed lack of effects of CDPPB alone on extracellular 
glutamate levels in the mPFC. 
The precise neurochemical circuits and signaling mechanisms underlying both the 
ability of MK-801 to increase extracellular glutamate in the mPFC, and its reversal by 
CDPPB are currently unknown and require further study. Both NMDA and mGluR5 
receptors are predominantly localized to postsynaptic membranes on dendritic spines 
(Gass & Olive, 2008; Niswender & Conn, 2010; Romano et al., 1995). Thus the effects of 
ligands on these receptors are not likely to be mediated by actions on presynaptically 
localized mGluR5 or NMDA receptors, though some investigators have reported 
evidence of small populations of cortical neurons expressing these receptors on 
presynaptic terminals (Corlew et al., 2008; Duguid, 2013; Romano et al., 1995). A more 
likely mechanism is that both CDPPB and MK-801 act on multisynaptic feedback 
mechanisms that regulate local glutamate levels in the mPFC. For instance, it has been 
demonstrated that local perfusion of NMDA antagonists into the mPFC does not evoke 
increases in extracellular glutamate (Lorrain et al., 2003), suggesting that NMDA 
antagonists act elsewhere in the brain to produce their effects on mPFC extracellular 
glutamate levels. It has been suggested that NMDA antagonists such as MK-801 inhibit 
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GABAergic inputs to mPFC glutamate neurons, and thus disinhibit local glutamate 
transmission (Olney & Farber, 1995; Moghaddam et al., 1997; Krystal et al., 2003; 
Yonezawa et al., 1998). In support of this suggestion, GABAergic interneurons in 
subcortical regions such as the limbic cortex and hippocampus appear to be more 
responsive to NMDA antagonists than cortical pyramidal neurons, indicating that low to 
moderate doses of MK-801 (Grunze et al., 1996; Li et al., 2002), similar to the dose used 
in the present study, may act in extra-mPFC regions to influence local GABAergic 
regulation of glutamatergic transmission in the mPFC. Consistent with this, mGluR5 
receptors in the cerebral cortex are predominantly localized to various types of 
GABAergic interneurons, but are relatively sparse on excitatory pyramidal cells (Kerner 
et al. 1997). Via their well-characterized facilitating effects on NMDA receptor function 
(Krystal et al., 2010; Niswender & Conn, 2010; Olive, 2009), mGluR5 PAMs may 
therefore restore impaired NMDA receptor functionality. Repeated administration of 
CDPPB has also been reported to increase total levels of NR1 subunits of the NMDA 
receptor as well as levels of phosphorylated NR1 and NR2B in the frontal cortex (Uslaner 
et al., 2009), providing another potential mechanism for the ability of mGluR5 PAMs to 
restore disrupted NMDA functionality.  
In summary, we have demonstrated that positive allosteric modulation of mGluR5 
receptors prevent the ability of the NMDA receptor antagonist MK-801 to increase 
extracellular glutamate levels in the mPFC, while showing no evidence of effect when 
administered alone. The ability of mGluR5 PAMs to reverse disruptions in excitatory 
transmission in the mPFC is consistent with their ability to reverse pharmacologically 
induced disruptions in cognitive function, and our findings lend further support to the 
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notion that mGluR5 PAMs may be novel approaches to restoring cognitive function in 
neuropsychiatric disorders such as schizophrenia and drug addiction. 
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CHAPTER 4 
EFFECTS OF MGLUR5 POSITIVE AND NEGATIVE ALLOSTERIC 
MODULATION ON DENDRITIC SPINE MORPHOLOGY IN THE MEDIAL 
PREFRONTAL CORTEX 
Abstract 
Rationale Metabotropic glutamate receptors (mGluR5) are highly involved in synaptic 
plasticity and are linked to proteins which are known to regulate dendritic spine density 
and spine morphology. However, no studies have examined how the positive or negative 
allosteric modulation of mGluR5 affects dendritic spine properties. Dendritic spine 
density and head are positively correlated with efficient synaptic transmission and 
cognition. Thus, drugs that exert this effect may be potential treatments for disorders that 
are associated with cognitive impairments. 
Objectives The purpose of this study was determine the effects of the positive and 
negative allosteric modulation of mGluR5 on dendritic spine density and measures of 
morphology including spine head diameter, length and volume in pyramidal neurons in 
the mPFC.  
Methods Male Sprague-Dawley rats were treated for ten consecutive days with either 3-
cyano-N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamide (CDPPB 20 mg/kg) or 1-(3-
chlorophenyl)-3-(3-methyl-5-oxo-4 H-imidazol-2-yl)urea (fenobam 20 mg/kg) or vehicle. 
Following the final drug or vehicle treatment, brain sections containing the mPFC 
underwent diolistic labeling and subsequent imaging by confocal laser scanning 
microscopy. 
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Results Compared to animals receiving vehicle, administration of fenobam significantly 
increased spine density and the overall frequency of spines with small (<20 m) head 
diameters, decreased the overall frequency of spines with slightly larger (20-40 m) head 
diameters, while showing no evidence of effect on the frequency of spines with larger 
head diameters (>40 m) of spine length or volume in the mPFC as compared to vehicle. 
Administration of CDPPB showed no evidence of effect on spine density, and neither 
treatment had any effect on spine length or volume. 
Conclusions These findings highlight functional differences between mGluR5 PAMs and 
NAMs with regards to their ability to regular structural plasticity in the mPFC.  
 
Introduction 
Cognitive impairments play a major role in several debilitating illnesses, such as 
drug addiction, Parkinson’s disease, Alzheimer’s disease, and schizophrenia. The extent 
of cognitive decline is a major determinant of functional outcome for everyday living as 
cognitive impairments can disrupt a person’s ability to maintain employment, 
relationships, and in some severe cases, appropriate daily hygiene. Cognitive 
impairments include deficits in working memory, reference memory, attention, set-
shifting strategy, verbal fluency, and other aspects of executive functioning (Green et al., 
2004; Hahn-Barma et al., 1998; Lawrence et al., 1998a,b; Lees & Smith, 1983; Silver et 
al., 2003; Snowden et al., 2002; Taylor et al., 1986). A patient’s level of cognitive 
function correlates strongly with treatment retention and compliance. For example, 
studies in substance abusing populations have shown that treatment dropouts had 
significantly poorer cognitive functioning than those who completed the treatment 
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program (Aharonovich et al., 2006). For patients with schizophrenia, cognitive functions 
were the strongest predictor of ability to properly manage medications (Jeste et al., 2003).  
Several cognitive enhancers, known as nootropics, have mechanisms of action 
that target several different neurotransmitter systems including serotonin, GABA, 
cholinergic, and glutamate transmission (Brady et al., 2011; Collingridge et al., 2013; 
Floresco & Jentsch, 2011; Hyman, 2011; Sofuoglu et al., 2013). Increasing attention has 
been directed towards targeting glutamatergic transmission for cognitive enhancement, as 
it is one of the primary mediators of synaptic plasticity (Bliss & Collingridge, 1993; 
Malenka & Nicoll, 1999; Song & Huganir, 2002). 
Glutamate is the most prevalent excitatory neurotransmitter in the central nervous 
system, mediating as much as 70% of both fast and slow excitatory neurotransmission 
(Olive, 2009). Glutamate receptors are either ligand-gated ion channels (i.e., ionotropic 
glutamate receptors, or iGluRs) or G-protein coupled receptors (i.e., metabotropic 
glutamate receptors, or mGluRs). iGluRs are ion channels that are permeable to cations, 
and function by allowing Na
+
 and Ca
2+
 to enter the cell initiating action potentials and 
activating various intracellular signaling pathways. iGluRs are located on the head of 
postsynaptic dendritic spines, mediate fast excitatory neurotransmission, and are divided 
into three different subtypes, N-methyl-D-aspartate (NMDA), α-amino-3-hydroxyl-5-
methyl-4-isoxazole-propionate (AMPA), and kainic acid (KA) (Olive, 2009). mGluRs are 
located on both presynaptic terminals and postsynaptic dendritic spines, (Conn & Pin, 
1997; Hermans & Challiss, 2001; Pin & Duvoisin, 1995). mGluRs mediate slower, 
modulatory neurotransmission, and based on their intracellular signaling and 
pharmacological properties, are categorized into three families. Group I mGluRs consists 
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of mGluR1 and mGluR5 receptors, Group II mGluRs consists of mGluR2 and mGluR3 
receptors, and Group III consists of mGluR4, mGluR6, mGluR7 and mGluR8 receptors 
(Olive, 2009). For the purposes of the present study, we will focus our discussions on 
Group I mGluRs. 
Group I mGluRs primarily utilize Gq/G11 signaling mechanisms which activate 
phosopholipase C to form diacylglycerol (DAG) and inositol triphosphate (IP3). DAG 
activates protein kinase C (PKC), while IP3 exerts further downstream effects by binding 
to IP3 receptors on the endoplasmic reticulum releasing intracellular Ca
2+
 which in turn 
activates other intracellular messengers such as calcium/calmodulin-dependent kinase II 
(CaMKII). PKC exerts further downstream effects by phosphorylating CREB and other 
signaling molecules which can eventually lead to altered gene transcription (Hermans & 
Challiss, 2001). Other intracellular signaling targets of Group I mGluRs include 
pathways involving Gi/o and Gs signaling, as well as the mitogen-activated protein 
kinase/extracellular signal-related kinase (MAPK/ERK) and mammalian target of 
rapamycin (mTOR)/p70 S6 kinase pathway, both of which are highly implicated in the 
regulation of synaptic plasticity (Hou & Klann, 2004; Iacovelli et al., 2002; Li et al., 
2007; Page et al., 2006; Saugstad & Ingram, 2008). 
Group I mGluRs, particularly mGluR5, are physically linked to NMDA receptors 
by various scaffolding proteins (such as Homer, Shank and GKAP), and positively 
modulate NMDA receptor function. Through its activation of PKC, mGluR5 activation 
also increases the phosphorylation of NMDA receptor subunits, thereby indirectly 
increasing the probability of NMDA receptor channel opening (Niswender & Conn, 
2010). Due to the postsynaptic localization of Group I mGluRs, these receptors primarily 
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initiate and regulate long-term potentiation (LTP) and long-term depression (LTD) by 
postsynaptic mechanisms such as potentiation of NMDA receptor function (Anwyl, 1999; 
Bellone et al., 2008; Gladding et al., 2009). These structural and biochemical interactions 
allow for the stimulation of group I mGluRs to activate NMDA receptors without 
inducing excitotoxicity (Albensi, 2007; Hardingham & Bading, 2003). 
Positive and negative allosteric modulators (PAMs and NAMs, respectively) are 
ligands that either facilitate or inhibit receptor functioning in the presence of glutamate 
binding to the orthosteric binding site. Thus, mGluR5 PAMs and NAMs are more 
indirect routes for modulating NMDA receptor function while reducing the possibility of 
adverse side effects such as excitotoxicity. Several studies have examined the effects of 
the administration of mGluR5 PAMs on cognitive enhancing abilities in impaired and 
unimpaired cognitive states. For example, pharmacologically induced cognitive deficits 
have been shown to be reversed by administration of mGluR5 PAMs in several different 
paradigms, including operant set-shifting tasks (Darrah et al., 2008; Gastambide et al., 
2013), spatial alteration tasks (Fowler et al., 2013; Stefani & Moghaddam, 2010), active 
allothetic place avoidance (Vales et al., 2010), reversal digging paradigms (Gastambide, 
2012), social novelty discrimination (Clifton et al., 2013), and novel object recognition 
(Horio et al., 2013; Reichel et al., 2011). PAM of mGluR5 also reversed induced sucrose 
impairments (Vardigan et al., 2010) and taste aversion and inhibitory avoidance tasks 
(Fowler et al., 2011). Notably, mGluR5 PAMs have also been shown to improve spatial 
and recognition memory abilities in unimpaired animals (Ayala et al., 2009; Balschun et 
al., 2006; Uslaner et al., 2009; Xu et al., 2013). 
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In contrast, various studies have shown that mGluR5 NAMs impair cognitive 
function in otherwise unimpaired animals. mGluR5 NAMs can impair performance on 
spatial and working memory tasks (Simonyi et al., 2010). Also, mGluR5 knockout (KO) 
mice show impaired performance in spatial memory tasks as well as acquisition and 
extinction of conditioned fear (Lu et al., 1997; Xu et al., 2009). However, not all studies 
have demonstrated cognitive deficits induced by mGluR5 NAMs (Petersen et al., 2002).  
Interestingly, mGluR5 NAMs have also been shown to improve aspects of 
cognitive impairment. Fragile X syndrome (FXS) is the most common inherited form of 
mental retardation (Gross et al., 2012). FXS is the result of either a deficiency or loss of 
function of the fragile X mental retardation 1 (FMR1) protein (McLennan et al., 2011). 
Models of Fragile X syndrome include fragile X mental retardation 1 (FMR1) protein KO 
mice. FMR1 KO mice display audiogenic and limbic seizures that are characteristic of 
FXS, and are rescued by treatment with mGuR5 NAMs such as 2-methyl-6-
phenylethynyl-pyridine (MPEP) (Yan et al., 2005) and 2-chloro-4-((2,5-dimethyl-1-(4-
(trifluoromethoxy)phenyl)-1H-imidazol-4-yl)ethynyl)pyridine (CTEP; Michalon et al., 
2012). In FXS patients, mGluR5 NAMs such as 1-(3-chlorophenyl)-3-(3-methyl-5-oxo-4 
H-imidazol-2-yl)urea (fenobam) have been shown to improve cognitive impairments 
(Berry-Kravis et al., 2009). As seen in FXS human tissue, FMR1 KO mice have an 
increased density of immature elongated spines, which is reversed by mGluR5 NAM 
treatment (Comery et al., 1997; Irwin et al., 1998; Pop et al., 2014).  
Spine structure is coordinated with synaptic function and plasticity (Penzes et al., 
2011). For example, larger spine sizes are induced by LTP and smaller spine sizes are 
induced by LTD (Kasai et al., 2010). Spine morphology is experience-dependent and 
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subtle changes in structure can have robust effects on synaptic function and connectivity 
in neuronal circuits (Penzez et al., 2011). Larger surface areas of dendritic spine heads 
allow more receptor insertion which results in more efficient synaptic neurotransmission 
(Shen et al., 2008). Postmortem studies on patients with schizophrenia show reduced 
dendritic spine density on pyramidal neurons, particularly in layer 3 neurons, in the 
dorsolateral prefrontal cortex (DLPFC) (Glantz & Lewis, 2000). This correlates with 
schizophrenia patients showing reduced activity of this region during cognitive tasks 
(Tan et al., 2007). FXS syndrome and several other diseases/syndromes (Alzheimer’s 
Disease and Autism Spectrum Disorders (ASD), have severe impaired cognitive 
functions, correlated with smaller spine size and density in cortical regions (Comery et 
al., 1997; Hustler et al., 2010; Irwin et al., 1998; Lancor et al., 2007; Pop et al., 2014; 
Shanker, 2007). The increasing dendritic spine size and density may ameliorate cognitive 
impairments in various CNS disorders. However, drugs of abuse can induce increases or 
decreases in dendritic spine density in various brain regions, depending on drug class 
(i.e., psychostimulants vs. opiates) (Robinson & Kolb, 2004; Gipson et al., 2014). 
Few studies have examined the effects of pharmacological manipulation of 
mGluR5 receptors on dendritic spine plasticity and morphology. Vanderklish and 
colleagues found that activation of Group I mGluRs increased spine length in 
hippocampal neurons in vitro, and Chen and colleagues found that embryonic KO 
mGluR5 mice resulted in increased spine density in the frontal cortex (Chen et al., 2012; 
Vanderklish et al., 2002). To our knowledge, one study to date examined the effects of 
mGluR5 PAMs on dendritic spine density and morphology in the frontal cortex, but this 
study utilized alcohol self-administration and extinction procedures (Gass et al., 2014). 
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Currently, no study has examined the effects of mGluR5 NAM on dendritic spine density 
and morphology in the frontal cortex. The objective of this study was to determine the 
effects of mGluR5 PAM 3-cyano-N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamide (CDPPB) 
and mGluR5 NAM fenobam on spine density, length, head diameter and overall volume.  
 
Methods and Materials 
 
Subjects 
Subjects were male Sprague-Dawley rats (Harlan Laboratories, Livermore, CA) 
weighing 250-300 g upon arrival. Rats were pair-housed and had ad libitum access to 
food and water under a 12 hr reversed light/dark cycle (lights off 7 am) throughout the 
duration of the study. The vivarium was held at a temperature of 22±1C, and animals 
were maintained in accordance with the guidelines described in the 8th edition of the 
Guide for the Care and Use of Laboratory Animals. All procedures and facilities were 
approved by the Institutional Animal Care and Use Committee at Arizona State 
University. 
 
Drugs Treatments 
3-cyano-N-1,3-diphenyl-1H-pyrazol-5-yl)benzamide (CDPPB) and 1-(3-
chlorophenyl)-3-(3-methyl-5-oxo-4H-imidazol-2-yl)urea (fenobam) were synthesized by 
Chemir Analytical Services (Maryland Heights, MO) according to previously published 
methods (Jaeschke et al., 2007; Kinney et al., 2005). Each drug was suspended in a 
vehicle consisting of 10% v/v Tween 80 (Sigma-Aldrich, St. Louis, MO) and 
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administered at a dose of 20 mg/kg via the subcutaneous (s.c.) route in a volume of 0.5 
ml for ten consecutive days. The dose selected for CDPPB and fenobam were based on 
previous studies by our laboratory and others that have demonstrated behavioral or 
cognitive effects of these compounds at similar doses (Ayala et al., 2009; Gass et al., 
2014; Horio et al., 2013; Stefani & Moghaddam, 2010; Uslaner et al., 2009; Montana et 
al., 2009; Watterson et al., 2013) and a lack of neurotoxicity in the mPFC (Gass & Olive, 
2009), which has recently been described as an adverse effect of higher doses of mGluR5 
PAMs (Parmentier-Batteur et al., 2013). 
 
Tissue Preparation  
Diolistic labeling of neurons was performed according to previously published 
procedures (Shen et al., 2008; Gass et al., 2014). Animals were deeply anesthetized with 
an injection of sodium pentobarbital (150 mg/kg) via the intraperitoneal (i.p.) route and 
perfused transcardially with 100 mL of phosphate-buffered saline (PBS, pH = 7.4) 
containing 0.1% w/v heparin followed by 200 mL of 1.5% w/v paraformaldehyde (pH = 
7.4) in 0.1 M PBS. After perfusion, brains were extracted and post-fixed in 1.5% 
paraformaldehyde (PFA) in PBS for one hour at room temperature. Brains were then 
sectioned on a vibratome (The Vibratome  Co., Series 1000, St. Louis, MO) sectioned in 
150 m serial coronal sections through the PFC. Sections were stored in 25 mM PBS at 
4˚C until diolistic labeling procedures. 
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Preparation of DiI-Coated Microparticles 
For preparation of dye-coated microparticles, the lipophilic carbocyanine 
fluorescent dye, 1,1-dioctadecyl-3,3,3,3-tetramethylindocarbocyanine perchlorate, DiI-
C18-(3) (DiI, Molecular Probes, Carlsbad, CA) was dissolved in dichloromethane and 
applied to 100 mg of 1.3-μm diameter tungsten particles (Bio-Rad, Hercules, CA) on a 
microscope slide. DiI-coated tungsten particles were scraped from the slide and added to 
10 ml of 10 mg/ml polyvinylpyrrolidone (PVP; Sigma-Aldrich). The DiI/PVP solution 
was sonicated and drawn into Tefzel tubing (Bio-Rad) which was pre-coated with 10 
mg/ml PVP. Particles were allowed to settle for 30 minutes, after which the PVP solution 
was carefully withdrawn from the tubing. The tubing was then dried under 0.4 L/min 
nitrogen gas for 20 min and then cut into small segments and protected from light until 
use. 
 
Delivery of DiI -Coated Tungsten Particles   
 A Helios gene gun (Bio-Rad) fitted with a polycarbonate filter (3.0 µm pore size) 
was used to deliver DiI-coated tungsten particles into the tissue sections via pressurized 
helium (85 psi). Each tissue section was removed from PBS and diolistically loaded with 
a single pulse of helium. After labeling, sections were re-suspended in PBS for 24 hours 
to allow DiI to diffuse into the cell membranes. Next, sections were submerged in a 4% 
PFA solution for one hour, washed with PBS and mounted on gelatin-coated microscope 
slides. Sections were covered with anti-fade mounting media to protect against 
photobleaching, coverslipped, and the edges were sealed with nail polish to prevent 
dehydration.  
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Confocal Imaging 
A Leica SP5 (Leica Microsystems, Buffalo Grove, IL) with Leica LAS AF 
software confocal microscope was used to acquire images of DiI labeled neurons. 
Sections were visualized at 568 nm excitation using a krypton-argon laser. The outline 
for each labeled neuron was acquired using a 63x/1.4 NA oil immersion objective and an 
XY pixel resolution of 2048 x 2048 at a frequency of 200 Hz. Each neuron was first 
scanned at 1.0 μm increments along the z axis to generate an overall image of the neuron 
and the dendrite to be analyzed, followed by a z-scan at 0.1 m intervals focusing on the 
apical dendrite of pyramidal neurons, as characterized by an extensively branched spiny 
dendrite, as opposed to the shorter basal dendrites. Imaged dendritic segments of 
identified pyramidal neurons were 70 - 120 μm from the soma. Other criterion for 
selected dendrites for analysis included being devoid of crossovers from other dendrites, 
positioned beyond the first branch point, and the dendrite segment analyzed was between 
50-80 μm in length. All dendritic segments imaged were located in the prelimbic (PL) or 
infralimbic (IL) regions of the PFC (N= 6-10 per animal). Localization of cortical layer 
was noted for each neuron and confirmed by comparison of the position of the neuron 
analyzed under low (10x) magnification and corresponding sections from a rat brain atlas 
(Swanson, 1999; Fig 3A).  
 
Quantitation and Analysis of Dendritic Spine Density and Spine Head Morphology 
Z-stacks of scanned dendrite segments were reconstructed using Imaris software 
(Version 7.5, Bitplane Inc., St. Paul, MN). Dendritic shafts and spines were manually 
traced using the Auto Depth function of the Filament module. Accurate quantification 
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was achieved using the diameter function. The minimum and maximum values for the 
dendrite diameter were set at ≥0.3 μm and ≤3.7 μm, respectively, and the fluorescence 
contrast threshold was set at 1.3 μm. The minimum and maximum values of the segment 
diameter for dendritic spines were set at ≥0.143 μm and ≤10.5 μm, respectively, and the 
fluorescence contrast threshold was set at 3 μm. These settings were adequate to 
distinguish all fluorescent edges which allowed for accurate representation of the shape 
and size of dendrites and spines analyzed (Shen et al., 2008; Gass et al., 2014). All 
dendritic and spine tracing were performed by an investigator blind to experimental 
treatment group. Figure 3B shows a scanned pyramidal neuron with traced dendritic 
segment and spines.  
 
Data Analyses 
Overall differences in each variable (spine density, volume, length, and head 
diameter) across treatment groups were analyzed using SAS (SAS Institute Inc., Research 
Triangle Park, NC) using mixed model (SAS Proc Mixed) procedure as we have used 
previously (Kroener et al., 2012; Gass et al., 2014). The procedure uses a first-order 
autoregressive covariance matrix across the sequential slices within each rat. Overall tests 
of significance are determined by Type 3 tests of fixed effects, and post-hoc comparisons 
are determined by differences in least squares means. Morphological characteristics of 
dendritic spines (length, volume, and head diameter) were also binned for frequency 
analyses (Shen et al., 2008), where the number of observations in each bin was expressed 
as a percent of the total number of observations for that particular variable. The following 
bin sizes were used: spine volume (0.05 m3), length (0.5 m), and head diameter (0.2 
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m). Binned data were analyzed by a two-way ANOVA with bin and treatment group as 
main factors, followed by Bonferroni post hoc tests using Prism version 5.0 (GraphPad, 
La Jolla, CA). P-values less than 0.05 were considered statistically significant for all 
analyses.  
 
Results 
 We observed a significant effect of treatment on dendritic spine density 
(F(2,21)=6.07, p<0.01), such that rats treated with fenobam exhibited significantly 
increased spine density as compared to rats treated with vehicle (Figure 3C, p<0.001). 
However, there was no evidence of an effect of CDPPB on spine density as compared to 
vehicle treated animals (p>0.05).   
 We also observed a significant effect of treatment on dendritic spine head 
diameter (F(2,21)=6.93, p<0.005), such that rats treated with fenobam exhibited 
significantly decreased spine density as compared to rats treated with vehicle (Figure 3D, 
p<0.005). Binned frequency analysis revealed that the reduction of spine head diameter 
by fenobam was accompanied by an increase in frequency of occurrence of spine heads 
with diameters <20 m (p<0.001) and a decrease in frequency of occurrence of spine 
heads with diameters between 20 and 40 m in medium sized spine heads (p<0.01). No 
group differences were observed in the frequency of occurrence of spine heads with 
diameters >40 m. In addition, CDPPB showed no evidence of effect on spine head 
diameter as compared to vehicle treated animals (p>0.05). 
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We found no evidence of effect for treatment on either spine length or volume, 
either as overall group differences of when data analyzed by binned frequency of 
occurrence (Figure 3E/F, p’s >0.05). 
 
Discussion 
The overall findings of this study are that repeated administration of the mGluR5 
NAM fenobam increases dendritic spine density in pyramidal neurons of the mPFC, 
while repeated treatment with the mGluR5 PAM CDPPB showed no evidence of effect 
on spine density. Analysis of spine head diameters revealed that fenobam treatment 
produced an overall reduction in spine head diameter, and binned frequency analysis 
revealed that fenobam treatment increased the frequency of occurrence of spine head 
diameters <20 m, decreased the frequency of occurrence of spine head diameters 
between 20 and 40 m, while leaving spine head diameters >40 mm unaffected. 
Suprisingly, CDPPB was without effect on spine density or spine head diameter. Finally, 
neither CDPPB nor fenobam treatment altered spine volume or length. 
Fenobam may increase spine density by acting as an antagonist on the mGluR5 
receptor, thus reducing mGluR5 activity. The reduction in mGluR5 activity may cause 
reduced NMDAR activity, which is critical for normal synaptic function. Therefore, 
increased spine density may be due to reduced neuronal signaling that may mediate 
cellular compensatory mechanisms in an effort to return stability to synaptic function. 
Dendritic spines are plastic and change rapidly as a function of behavior, hormonal 
status, and synaptic activity (Brandon & Cross, 1982; Horner, 1993; Woolley et al., 
1990). mGluR5 activation affects several postsynaptic scaffolding proteins (such as 
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Homer, GKAP, and Shank) as well as intracellular signaling cascades including PKC and 
phosphoinositol signaling, all of which influence synaptic maturation and plasticity 
(Chen et al., 2012). Proper functioning of mGluR5 and NMDAR are essential for 
neuronal cytoarchitectural maturational processes, including dendritic morphology, 
axonal arborization (She et al., 2009; Wijetunge et al., 2008), and spine density (Datwani 
et al., 2002). Studies that support this notion include findings that mGluR5 knockout 
(KO) mice showed significant increases in spine density in layer IV of the cerebral cortex 
(Chen et al., 2012), and deletion of NR1 subunit in NMDAR also produces an increase in 
spine density (Datwani et al., 2002). mGluR5 may indirectly regulate synaptic plasticity 
mediated by NMDARs (Harney et al., 2006), as inhibition of mGluR5 leads to a 
reduction of NMDAR currents (Lu et al., 1997). The above studies are consistent with 
our findings, and overall it appears that decreased mGluR5 and/or NMDAR function 
causes increased spine density.  
Fenobam caused an increase in the frequency of spines with smaller terminal head 
point diameter and decreased the frequency of spines with medium terminal head point 
diameters, when compared to CDPPB and vehicle groups. However, CDPPB and vehicle 
groups showed no significant differences. Spines with smaller terminal head point 
diameter may be caused by mGluR5-mediated reduced NMDAR activity. Lack of 
excitatory function could increase the frequency of spines with smaller head size 
diameter as a result of cellular compensatory mechanisms. In an effort to maintain stable 
excitatory function, spinogenesis may occur to facilitate neurotransmission. Spine 
formation is often preceded by the development of filopodium-like or immature/thin 
spines, which are characterized as having small head diameter (Dailey et al., 1996; 
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Morest, 1969; Papa et al., 1995; Ramoa et al., 1987; Ulfhake & Cullheim, 1988). 
Filopodium-like spines have the potential to grow into mature spines and regulate 
synaptic function (Feng et al., 2002; Grutzendler et al., 2002; Parnass et al., 2000; 
Trachtenberg et al., 2002).  Intracellular proteins that physically link mGluR5 and 
NMDAR also influence spine morphology. As mentioned earlier, mGluR5 and NMDAR 
are linked primarily by proteins such as Shank and Homer, but several other post synaptic 
proteins are involved as well. PSD-95 binding proteins link Shank to NDMAR (Boeckers 
et al., 1999; Naisbitt et al., 1999; Tu et al., 1999) and Homer binds to Shank, mGluR5 
and IP3 (Naisbitt et al., 1999; Tu et al., 1999; Xiao et al., 2000). Through these 
connections, Shank can link NMDAR and mGluR5 (Sala et al., 2001).  Shank promotes 
the enlargement of spine heads via mechanisms that depend on the post synaptic 
recruitment and binding of Homer (Lim et al., 1999; Sala et al., 2001). Homer can 
promote spine enlargement by activating intracellular Ca
2+
 release in response to 
activation of mGluRs (Tu et al., 1998; Xiao et al., 1998).  Relevant to the current study, 
fenobam acts as an antagonist on mGluR5 and indirectly reduces NMDAR activity, 
thereby reducing overall intracellular Ca
2+
 levels. This could lead to a disruption of 
mechanisms that would normally induce spine maturation causing a higher frequency of 
immature spines. This conclusion is consistent with a study by Chen and colleagues 2012 
that found mGluR5 KO mice show significant increases in small spines in layer IV of the 
cerebral cortex (Chen et al., 2012), and is also consistent with the results of our study that 
fenobam increases the frequency of spines with smaller terminal head point diameter.   
CDPPB resulted in no significant differences on spine head diameter when 
compared to vehicle. The reasons for this are currently unclear, since mGluR5 PAMs are 
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known to facilitate the induction of plasticity at hippocampal synapses (Ayala et al., 
2009) and alter the expression of NMDA receptor subunits in the mPFC (Uslaner et al., 
2009). However, recent published literature has demonstrated that following alcohol self-
administration, repeated administration of a similar dose of CDPPB showed no evidence 
of effect on dendritic spine density or morphology in the mPFC when rats were subjected 
to forced abstinence in the home cage. Alternatively, a separate group of rats underwent 
extinction training following alcohol self-administration, CDPPB produced and increase 
in dendritic spine density, maturity, and AMPA-mediated calcium currents selectively in 
the infralimbic cortex (Gass et al., 2014). This suggests an interaction between CDPPB 
and engagement in behaviors known to invoke activity of the mPFC in order to produce 
discernible changes in spine density or morphology. Finally, the lack of observed effects 
in spine length, volume, density, or head diameter in CDPPB treated rats are consistent 
with findings that repeated administration of CDPPB (30 mg/kg) found no evidence of 
neurotoxicity in the mPFC (Gass & Olive, 2009). This is particularly important in light of 
recently published evidence that high doses of mGluR5 PAMs can produce neuronal 
necrosis in the auditory cortex and hippocampus (Parmentier-Batteur et al., 2013).   
Both fenobam and CDPPB revealed no significant difference on spine length or 
spine volume. This may be due to several factors, including short half-life of both drugs, 
and/or the slower modulatory effects of PAMs and NAMs as well as their allosteric mode 
of action. CDPPB has a half-life of 4 hrs (Kinney et al., 2005), and fenobam has a half-
life of 1 hr (Keck et al., 2013). Animals were treated once daily, thus subsequent studies 
may detect additional significant group differences by administering drugs twice daily.  
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It should be noted that while CDPPB and fenobam are both PAMs and NAMs, 
respectively, they have different postsynaptic effects. CDPPB slowly facilitates mGluR5 
activity, while fenobam indirectly blocks all mGluR5 activity (Keck et al., 2013; Kinney 
et al., 2005). The different effects on mGluR5 activity may explain why significant 
differences were observed between fenobam and vehicle, but not CDPPB and vehicle, on 
spine density and spine head diameter. Additionally, spines are highly plastic and 
undergo continual actin-based motility from seconds to minutes (Fisher et al., 1998; 
Matus et al., 2000). Because of the dynamic nature of spine morphology, it may be that 
spines are able to rapidly adapt to drug-induced changes, ultimately resulting in fewer 
group differences.  
In summary, this study showed that negative allosteric modulation of mGluR5 
receptors increased spine density and frequency of spines with smaller head diameter, 
while showing no evidence of effect on spine length or volume in the mPFC. Positive 
allosteric modulation of mGluR5 receptors were found to show no evidence of effect on 
spine density, spine head diameter, and spine length or spine volume. Our findings 
suggest that negative allosteric modulation of mGluR5 may cause neuronal compensatory 
mechanisms to stabilize synaptic function. However, since there are few other studies on 
the effects of mGluR5 PAMs and NAMs on dendritic spine density and morphology, 
future studies utilizing other doses, durations of treatment, and in animal models of 
neuropsychiatric diseases are clearly warranted. 
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CHAPTER 5 
SUMMARY AND DISCUSSION 
Summary of Experiments 
 Prior studies have shown that mGluR5 PAMs alleviate experimentally induced 
cognitive impairments in models of schizophrenia in rodents (Darrah et al., 2008; 
Gilmour et al., 2013; Stefani & Moghaddam, 2010; Vales et al., 2010). The aims of the 
current studies were to examine the effects of the mGluR5 PAM CDPPB on cognitive 
function and neurotransmission utilizing an MK-801-induced model of schizophrenia. 
Additionally, we examined the effects of CDPPB on dendritic spine plasticity, which has 
been suggested to underlie the cognitive impairments associated with schizophrenia 
(Glantz & Lewis, 2000; Tan et al., 2007). Experimental results revealed that pretreatment 
of CDPPB reverses cognitive and neurochemical MK-801-induced effects, but that 
chronic treatment of CDPPB produced no detectable effects on the structural plasticity of 
neurons.  
Experiment 1 showed that in a delayed matching/non-matching to sample task, 
CDPPB administration 30 min prior to MK-801 administration was able to prevent 
cognitive impairments, as compared to simultaneous administration of CDPPB and MK-
801, which showed only a slight reversal of impairments. Experiment 2 revealed that 
chronic administration of MK-801 significantly increases extracellular glutamate levels 
in the mPFC, and these effects were reversed by chronic CDPPB pretreatment. 
Experiment 3 showed that CDPPB administered alone caused no significant differences 
on the structural plasticity of dendritic spines, as measured by dendritic spine density and 
spine morphology. Interestingly, the mGluR5 NAM fenobam produced significant 
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increases in dendritic spine density and in the overall frequency of spines with smaller 
head diameters. 
 
Discussion 
 
Objective of Dissertation  
 Current medications are inadequate for treating the cognitive impairments 
observed in schizophrenia. Although the published literature is often contradictory, it 
appears that there is actually little clinical difference between the two classes of current 
antipsychotics medications (Green et al., 1997; Jones et al., 2006; Meltzer & McGurk, 
1999; Lewis & Lieberman, 2008; Silver et al., 2003; Stroup et al., 2003). Because of the 
current lack of drug efficacy, additional research and drug development is necessary to 
further improve the quality of life for patients with schizophrenia.   
The intent of this project was to assess the viability of mGluR5 PAMs as a 
possible novel approach for treating the cognitive impairments observed in patients with 
schizophrenia. While there are several ligands that act as mGluR5 PAMs, the current 
studies use the prototypical mGluR5 PAM, CDPPB, to pharmacologically enhance 
mGluR5 activity. Additionally, all experimental groups utilized a chronic treatment 
regimen to more closely model daily dosing patterns in humans.  
The first experiment of this research project examined the effects of CDPPB on 
cognitive flexibility using a pharmacological model of schizophrenia. Cognitive 
flexibility is impaired in patients with schizophrenia and is observed by several 
behaviors, one being perseveration (Milner, 1963). Patients with schizophrenia have been 
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shown to perform worse than healthy controls on cognitive flexibility tasks, as measured 
by rates of perseverative responses (Franke et al., 1992; Milner, 1963). The Wisconsin 
card sorting task is a neuropsychological test implemented to assess cognitive set-shifting 
abilities, and is suggested to be an indicator of dorsolateral PFC (DLPFC) function 
(Franke et al., 1992; Goldberg et al., 1987; Joel et al., 1997). Cognitive set-shifting is 
thought of as an executive function, and is suggested to involve the integration of 
planning, response inhibition, working memory and problem solving (Duke & Kaszniak, 
2000; Grafman & Litvan, 1999; Stuss & Alexander, 2000). Our first study utilized an 
operant cognitive set-shifting task that assessed the effects of CDPPB pretreatment on 
MK-801 induced impaired cognitive flexibility, as measured by rate of correct responses 
following task reversal. This study incorporated a delayed matching/non-matching-to-
sample component, which increased the working memory load, and thus the difficulty of 
the task (Dudchenko, 2004, Dudchenko et al., 2013). Cognitive flexibility is suggested to 
be PFC-dependent (Franke et al., 1992; Goldberg et al., 1987; Joel et al., 1997). 
Therefore, the effects of CDPPB on extracellular glutamate levels in the mPFC were 
measured in Experiment 2.  
Our second experiment assessed the effects of CDPPB when administered alone 
and as a pretreatment to MK-801 on extracellular glutamate levels in the mPFC. Gray 
and Roth (2007) posited that hyper-glutamatergic function may lead to hypofunctional 
NMDAR via excitotoxicity. NMDAR hypofunctioning is a leading hypothesis for the 
pathophysiology of schizophrenia, and has been suggested to underlie cognitive 
impairment, as well as the other symptoms of schizophrenia (Olney et al., 1999). 
  86 
Several published studies have reported that MK-801 increases extracellular 
glutamate levels in the mPFC, and these effects are reversed by traditional antipsychotics 
(Adams & Moghaddam, 2001; Lena et al., 2006; Lopez-Gil et al., 2007; Lopez-Gil et al., 
2009; Lorrain et al., 2003; Moghaddam et al., 1997; Pietraszek et al., 2009; Roenker et 
al., 2011; Roenker et al., 2012; Zuo et al., 2006). Therefore, this study assessed the ability 
of CDPPB to reduce MK-801 induced extracellular glutamate levels, and thus provide 
further support for the use of mGluR5 PAMs as a novel mechanism for treating the 
cognitive impairments observed in schizophrenia patients.  
 Dendritic spine structure is coordinated with synaptic function and plasticity 
(Penzez et al., 2011). Neuronal structure and morphology in the dorsolateral PFC 
(DLPFC) have been associated with cognitive function in patients with schizophrenia. 
During cognitive tasks patients showed reduced activity in the DLPFC (Tan et al., 2007), 
and postmortem analyses showed reduced dendritic spine density in this region (Glantz & 
Lewis, 2000). Therefore, increasing dendritic spine density and spine morphology in the 
mPFC may reduce cognitive impairments. Thus, our final study measured the effects of 
positive and negative allosteric modulation of mGluR5 manipulation, on the structural 
plasticity of neurons in the mPFC.  
The culmination of these experiments sought to tie together the effects of CDPPB 
on cognitive impairment, dysregulated glutamate transmission, and structural dendritic 
plasticity in the mPFC. Together, our findings support the notion of mGluR5 PAMs as 
novel treatment approaches for cognitive impairments in patients with schizophrenia.  
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Summary of Results 
In experiment 1, animals pretreated with CDPPB 30 min prior to MK-801 showed 
significant increases in correct responding as compared to animals treated with 
vehicle/MK-801. Furthermore, pretreatment with CDPPB prior to MK-801 resulted in 
performance of correct responses that were equivalent to vehicle/vehicle treated animals. 
Simultaneous treatment with CDPPB and MK-801 produced only partial attenuation of 
MK-801 induced deficits on set-shifting ability, as compared to vehicle/MK-801 treated 
animals.  
In experiment 2, no significant differences were observed in AUC values for 
baseline (samples 1-4) between treatment groups.  Analyses of post-injection AUC values 
revealed significant effects of treatment group. Post hoc analyses revealed that post-
injection AUC values were significantly elevated in vehicle/MK-801 treated animals as 
compared to vehicle/vehicle treated animals, indicating that MK-801 produced an 
elevation in extracellular levels of glutamate in the mPFC. Post-injection AUC values in 
CDPPB/MK-801 treated animals were significantly decreased as compared to 
vehicle/MK-801 treated animals, indicating a reversal of MK-801 induced increases in 
extracellular glutamate by pretreatment with CDPPB. No significant differences were 
detected in post-injection AUC values between vehicle/vehicle and CDPPB/MK801 
treated animals, and no significant differences were detected in Post-injection AUC 
values between vehicle/vehicle and CDPPB/vehicle treated animals. These latter negative 
results suggest that administration of CDPPB alone does not alter extracellular levels of 
glutamate in the mPFC.  
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In experiment 3, animals treated with the mGluR5 NAM fenobam revealed a 
significant increase in spine density as compared to animals treated with vehicle. 
However, CDPPB treatment produced no changes in spine density when compared to 
vehicle treatment. Animals treated with fenobam showed overall reduced spine head 
diameters as compared to both vehicle and CDPPB treated animals. Frequency analysis 
revealed that the reduction of spine head diameter by fenobam was associated with an 
increase in frequency of the smallest spine heads, and a decrease in medium sized spine 
heads as compared to vehicle treatment. Animals treated with fenobam or CDPPB 
produced no significant differences on spine length or spine volume, as compared to 
vehicle. 
Results of primary importance include the ability of mGluR5 PAM to prevent MK-
801 induced cognitive impairments, as well as MK-801 induced elevated extracellular 
glutamate levels. Interestingly, the effects of mGluR5 PAM and NAM treatment on spine 
density and spine morphology were surprising, as we had expected that CDPPB, rather 
than fenobam, would increase spine density. Careful interpretation and critical 
comparison to established literature is necessary to determine the contribution of these 
results to future research on schizophrenia.  
 
Interpretation of Results: Experiment 1 
Experiment 1 demonstrated that pharmacological blockade of NMDA receptors 
with MK-801 produced deficits in a delayed matching/non-matching-to-sample operant 
set-shifting task, and these effects were prevented when the mGluR5 PAM CDPPB was 
administered 30 minutes prior to, but not simultaneously with MK-801. Simultaneous 
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administration of CDPPB and MK-801 resulted in a partial reversal of MK-801 induced 
deficits. Our results are consistent with findings from several other studies that 
administered mGluR5 PAMs to reverse MK-801 induced deficits, but in non-delay based 
operant tasks. Such paradigms previously studied include: spatial alteration tasks (Fowler 
et al., 2013); novelty discrimination (Clifton et al., 2013); novel object recognition (Horio 
et al., 2013; Reichel et al., 2011; Uslaner et al., 2009); and active allothetic place 
avoidance (Vales et al., 2009). mGluR5 PAMs have also been shown to reverse MK-801 
induced impairments in sucrose preference (Vardigan et al., 2010), taste aversion and 
inhibitory avoidance tasks (Fowler et al., 2011), and alterations in PFC neuronal firing 
patterns (Lecourtier et al., 2007; Homayoun et al., 2008; Homayoun & Moghaddam, 
2010). Notably, these studies did not administer CDPPB as a pretreatment, and drug 
administration was either acute or subchronic, whereas the current study utilized a 
chronic treatment regimen. Stefani and Moghaddam (2010) utilized a pretreatment 
regimen, but they administered MK-801 prior to CDPPB. Interestingly, their results were 
consistent with ours, showing a prevention of MK-801 induced impairments in a spatial 
maze plus task. However, in this study both treatments were administered acutely, 
whereas our treatments were administered chronically. It may be possible that the order 
of ligand administration may become more important when treatment regimen is chronic 
rather than acute. It should be noted that CDPPB has shown enhancement on spatial and 
recognition tasks in the absence of any impairment (Ayala et al., 2009; Balschun et al., 
2006; Uslaner et al., 2009). 
To our knowledge, few previous studies have examined the ability of mGluR5 
PAMs to reverse pharmacologically induced cognitive deficits in an operant set-shifting 
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paradigm (Darrah et al., 2008; Gastembide et al., 2012; Gastembide et al., 2013; Gilmour 
et al., 2013). Operant-based paradigms offer the advantage of modeling tasks used to 
assess cognitive flexibility and perseveration in humans, such as the Wisconsin Card 
Sorting Task (Franke et al., 1992; Goldberg et al., 1987; Joel et al., 1997; Silver et al., 
2003). Additionally, operant-based paradigms are PFC-dependent, as is cognitive 
flexibility (Franke et al., 1992; Goldberg et al., 1987; Joel et al., 1997). Cognitive set-
shifting is an executive function that involves attention, inhibition of response, working 
memory and planning/problem solving, all of which have been associated with DLPFC 
(Duke & Kaszniak, 2000; Grafman & Litvan, 1999; Stuss & Alexander, 2000). Spatial 
tasks are hippocampal dependent, and are therefore inappropriate for measuring PFC-
dependent cognitive flexibility (Aggleton et al., 1986; Olton & Paras, 1979). Two rodent 
studies which utilized DMS/DNMS and DMTP tasks found that mPFC lesions produced 
profound deficits in performance on set-shifting, while hippocampal lesions had no 
evidence of an effect on the ability to set-shift (Joel et al., 1997; Sloan et al., 2006). 
Secondly, there is a delay component involved in this task, which increases the working 
memory load (Dudchenko, 2004, Dudchenko et al., 2013), and therefore the difficulty of 
the task. Because of these two components, this task has high translational value for 
assessing cognitive flexibility in humans.    
 Gilmour and colleagues (2013) trained rats to respond for food in a delayed non-
matching-to-position nose poke paradigm. As far as we know, this is the only other study 
to utilize a delay component with positive findings. However, this study tested the 
efficacy of the novel mGluR5 PAMs LSN2463359 and LSN2814617 on reversal of set-
shifting performance deficits induced by the competitive (closed channel) NMDA 
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receptor antagonist SDZ 220,581. The efficacy of these mGluR5 PAMs were not 
assessed against the more widely used non-competitive (open channel) NMDA 
antagonists such as MK-801 or PCP. 
It could be argued that in the present study, the behavioral effects of CDPPB 
and/or MK-801 following task reversal may have resulted from drug accumulation in the 
plasma or brain during chronic drug administration prior to task reversal. The plasma 
elimination half-lives of CDPPB in rats are approximately 4 and 2 hrs, respectively 
(Kinney et al., 2005; Vezzani et al., 1989), and with chronic administration such an 
accumulation could indeed occur. However, some observations in the present study argue 
against this possibility. Should any behavioral effects of CDPPB have carried over from 
the pre-reversal to the post-reversal phase, these effects would likely have been observed 
in both the CDPPB/MK-801 and CDPPB 30 min/MK-801. However, this was not the 
case, since a prevention of MK-801 effects occurred only in animals receiving CDPPB 30 
min prior to MK-801.   
To further clarify this issue, a second control study was performed administering 
drug treatments only after task reversal. Initiation of all drug treatments following task 
reversal did not produce any deficits in acquiring the new task, suggesting a lack of 
carryover effects of MK-801 from the acquisition task phase to the reversal task phase. 
These observations are consistent with various bodies of literature suggesting that 
impaired NMDA receptor function at low to moderate doses does not lead to deficits in 
initial task learning (Chadman et al., 2006; Harder et al., 1998; Murray et al., 1995; 
Palencia & Ragozzino, 2004; van der Meulen et al., 2003; van der Staay et al., 2011; 
Wozniak et al., 1990), but appears to have more deleterious effects on set-shifting, which 
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result in behavioral and cognitive perseveration (Braff et al., 1991; Egerton et al., 2005; 
Franke et al., 1992; Goldberg et al., 1987; Green et al., 2004; Silver et al., 2003). Finally, 
it has previously been demonstrated that long-term cognitive impairing effects of 
chronically administered MK-801 are predominantly observed at high doses (i.e., 0.2 
mg/kg; Li et al., 2011), and not at the dose used in the present study (0.06 mg/kg).Taken 
together, we can interpret that chronic treatment during the acquisition task phase does 
not affect the validity of findings from the task reversal phase of the first experiment. 
Thus, we can conclude that the ability of MK-801 to induce deficits in set-shifting, and 
its reversal by pretreatment with CDPPB are mediated by continued drug administration 
following task reversal. Additionally, the effects of CDPPB in reversing induced deficits 
are consistent with the published literature.   
 
Significance of Findings: Experiment 1 
 This study has resulted in several significant and novel findings. To our 
knowledge, this is the first study to show that pretreatment of CDPPB prevents MK-801 
induced deficits on perseverative responding in a cognitive set-shifting task. Few studies 
have utilized an operant based cognitive set-shifting task, which is important as set-
shifting is a PFC–dependent task, and only one other study incorporated a delay 
component, which is important for taxing working memory load. The current study 
utilized chronic drug administration in order to more closely resemble daily intake 
patterns that are generally required for therapeutic purposes in humans. The delay 
component and chronic treatment regimen of this study are two novel attributes that 
provide increased clinical applicability. Other findings from the current study include 
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results suggesting that MK-801 does not impair the acquisition of learning, but rather the 
ability to shift tasks.  
CDPPB potentiates mGluR5 function, which indirectly increases NMDAR function 
and thus counters the NMDAR antagonism by MK-801. One of the leading hypotheses 
for the pathophysiology of schizophrenia is NMDAR hypofunction, thus MK-801 acting 
as an NMDAR antagonist may model this proposed pathology. The ability of CDPPB to 
counteract the effects of MK-801 is significant, as it lends further support for targeting 
mGluR5 with PAMs as a novel treatment to aid with cognitive impairments associated 
with schizophrenia.  
This study adds novel and significant findings to established research. 1) CDPPB 
pretreatment prevents deficits in an animal model of schizophrenia. 2) High translational 
value due to the cognitive set-shifting task utilized in this study, and 3) chronic (42 day) 
treatment regimen which is more analogous to chronic daily dosing in humans. Due to 
the above listed findings, this study lends significant support for utilizing PAM of 
mGluR5 as a novel treatment for the cognitive impairments associated with 
schizophrenia. 
 
Interpretation of Results: Experiment 2 
Experiment 2 showed that pretreatment with CDPPB significantly attenuated MK-
801 induced increases in extracellular glutamate in the mPFC. This finding implicates 
potential neurochemical substrates for the pro-cognitive effects of mGluR5 PAMs. 
Several literature sources show that CDPPB and other mGluR5 PAMs reverse 
pharmacologically induced performance deficits in PFC-mediated cognitive tasks such as 
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set-shifting (Stefani and Moghaddam, 2010; Gilmour et al., 2013; Horio et al., 2013; 
Darrah et al., 2008; LaCrosse et al., 2014). The published literature that is consistent with 
our finding that CDPPB reverses MK-801 induced dysfunction include an 
electrophysiological study, which demonstrated that CDPPB prevents MK801-induced 
increases in spontaneous activity of pyramidal neurons in the mPFC, and also normalizes 
MK-801 induced disruption in burst activity of these neurons (Lecourtier et al., 2007). 
Furthermore, repeated administration of CDPPB has been reported to increase total levels 
of NR1 subunits of the NMDA receptor as well as levels of phosphorylated NR1 and 
NR2B in the frontal cortex (Uslaner et al., 2009), providing another potential mechanism 
for how mGluR5 PAMs are able to reverse disrupted NMDA functionality. Critical 
evaluation of our results as compared to published literature suggests that PAM of 
mGluR5 function may be a mechanism by which to reverse disrupted excitatory 
neurotransmission in the mPFC, which may underlie cognitive impairments in 
schizophrenia. 
Administration of MK-801 significantly increases extracellular glutamate levels in 
the mPFC. This finding is consistent with several other studies that show acute treatment 
with MK-801 and other NMDAR antagonists increase extracellular glutamate levels in 
the mPFC (Adams & Moghaddam, 2001; Lena et al., 2006; Lopez-Gil et al., 2007, 2009; 
Lorrain et al., 2003; Moghaddam et al., 1997; Pietraszek et al., 2009; Roenker et al., 
2011; 2012; Zuo et al., 2006). This is an interesting result, as it seems counter-intuitive 
that NMDAR antagonists would cause an increase in extracellular glutamate levels. In 
fact, it has been demonstrated that local perfusion of NMDAR antagonists into the mPFC 
does not increase extracellular glutamate (Lorrain et al., 2003), which suggests that 
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NMDAR antagonists act elsewhere in the brain to produce their effects on mPFC 
extracellular glutamate levels. It has been suggested that NMDAR antagonists such as 
MK-801 block excitatory input onto GABAergic interneurons in the cerebral, which 
tonically inhibit mPFC glutamate neurons. Thus, MK-801 may cause disinhibition of 
glutamate transmission, ultimately leading to the observed increase in extracellular 
glutamate levels (Olney & Farber, 1995; Moghaddam et al., 1997; Krystal et al., 2003; 
Yonezawa et al., 1998). In support of this hypothesis, GABAergic interneurons in 
subcortical regions such as the limbic cortex and hippocampus appear to be more 
responsive to NMDAR antagonists than cortical pyramidal neurons (Kerner et al., 1997). 
Additionally, mGluR5 receptors in the cerebral cortex are predominantly localized to 
various types of GABAergic interneurons and are relatively sparse on excitatory 
pyramidal cells (Kerner et al., 1997). Via their well-characterized facilitatory effects on 
NMDAR function (Krystal et al., 2010; Niswender & Conn, 2010; Olive, 2010), mGluR5 
PAMs may therefore restore impaired NMDA receptor functionality. Thus, we can 
interpret that low to moderate doses of MK-801 may act in extra-mPFC regions to 
influence local GABAergic regulation of glutamatergic transmission in the mPFC 
(Grunze et al., 1996; Li et al., 2002).  
Administration of CDPPB alone produced no detectable effects on extracellular 
glutamate levels in the mPFC. Since the effects of CDPPB on extracellular glutamate 
levels have been largely unexamined, future studies employing other doses of CDPPB, as 
well as longer or shorter treatment regimens are necessary to further confirm this lack of 
effect. Other studies have reported that activation of mGluR5 receptors with orthosteric 
agonists can increase basal or evoked glutamate release from the forebrain and other 
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brain regions (de Novellis et al., 2003; Fazal et al., 2003; Thomas et al., 2000; Pintor et 
al., 2000; Reid et al., 1999). However, it is possible that the slower modulatory effects of 
mGluR5 PAMs may contribute to the observed lack of effects of CDPPB on extracellular 
glutamate levels in the mPFC.  
No significant differences in basal levels of extracellular glutamate were observed 
across all four treatment groups. This is surprising for a few reasons: 1) we utilized a 
chronic (ten day) treatment regimen which is likely to alter basal levels of glutamatergic 
transmission, 2) it is well established that acute MK-801 administration results in 
elevated increased extracellular glutamate levels as shown by our results and several 
other studies, and 3) Zuo and colleagues (2006) demonstrated that repeated 
administration of MK-801 daily for seven days actually reduced extracellular levels of 
glutamate in the mPFC, while acute MK-801 administration increased extracellular 
glutamate levels, but this study used a very high dose of MK-801 (0.6 mg/kg). Based on 
our results, as compared to established literature it can be interpreted that our MK-801 
dose (0.06 mg/kg) was inadequate to cause the same neuronal adaptations that are 
required to lower extracellular levels of glutamate in the mPFC. Chronic administration 
of CDPPB resulted in no evidence of an effect on extracellular basal glutamate levels is 
consistent with behavioral studies showing that CDPPB lacked evidence of an effect on 
cognitive tasks without a pre-existing deficit (Darrah et al., 2010), and inconsistent with 
others showing that CDPPB enhanced task performance on spatial and recognition tasks 
in the absence of a pre-existing deficit (Ayala et al., 2009; Balschun et al., 2006; Uslaner 
et al., 2009). However, Experiment 3 of this dissertation is consistent with the current 
study’s findings, showing that chronic administration of CDPPB had no observable 
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effects on dendritic spine plasticity in the mPFC, which is largely mediated by 
extracellular glutamate. 
The precise neurochemical circuits and signaling mechanisms underlying both the 
ability of MK-801 to increase extracellular glutamate in the mPFC, and its reversal by 
CDPPB, are currently unknown and require further study. Both NMDA and mGluR5 
receptors are predominantly localized to postsynaptic membranes on dendritic spines 
(Gass & Olive, 2008; Niswender & Conn, 2010; Romano et al., 1995), and thus the 
effects of ligands of these receptors are not likely to be mediated by actions on 
presynaptically localized mGluR5 or NMDA receptors, though some investigators have 
reported evidence of small populations of cortical neurons expressing these receptors on 
presynaptic terminals (Corlew et al., 2008; Duguid, 2013; Romano et al., 1995). A more 
likely mechanism is that both CDPPB and MK-801 act on multisynaptic feedback 
mechanisms that regulate local glutamate levels in the mPFC. 
Based on our results, as compared to the previously published results, we hypothesize 
that the ability of mGluR5 PAMs to reverse MK-801 induced disruptions in excitatory 
transmission in the mPFC may underlie the reversal of pharmacologically induced 
disruptions in cognitive function, as shown in Experiment 1 and other published research. 
Thus, we hypothesize that mGluR5 PAMs may normalize NMDA antagonist-induced 
dysregulatedglutamatatergic function in the mPFC.  
 
Significance of Findings: Experiment 2 
Of primary significance is our finding that pretreatment with CDPPB significantly 
attenuated MK-801 induced increases in extracellular glutamate in the mPFC. This is an 
  98 
important finding that implicates potential neurochemical substrates for the pro-cognitive 
effects of mGluR5 PAMs. Additionally, our study showed that MK-801 administration 
increases extracellular glutamate levels in the mPFC. This is consistent with established 
literature, and furthermore the effects of MK-801 on the glutamate system provide 
support for the excitotoxicity hypothesis of schizophrenia. This hypothesis suggests that 
hyperglutamatergic functioning can lead to excitotoxic cell death and cause NMDAR to 
be hypofunctional (Gray & Roth, 2007).  Therefore, two significant outcomes are 
provided by these findings. First, the ability of CDPPB administration to reverse 
pharmacologically induced elevated extracellular glutamate levels indicates the potential 
efficacy for use of mGluR5 PAMs as a possible novel treatment for schizophrenia. 
Secondly, the effects of MK-801 offer further insight and support to the NMDA 
hypofunction hypothesis of schizophrenia. Our findings that CDPPB shows no evidence 
of effect on extracellular glutamate levels is meaningful due to the fact that this is the first 
study to measure the effects of mGluR5 PAMs on extracellular glutamate using in vivo 
microdialysis procedures.  
This study adds novel and significant findings to established research. 1) CDPPB 
pretreatment is effective at reversing pharmacologically induced elevated extracellular 
glutamate levels in the mPFC. 2) Administration of CDPPB alone showed no evidence of 
an effect on extracellular glutamate, and 3) these results inform future research directions, 
including replication of our own findings, as well as studies to further elucidate the 
neurochemical circuits and signaling mechanisms underlying both the ability of MK-801 
to increase extracellular glutamate in the mPFC, and its reversal by CDPPB, which are 
currently unknown.  
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Interpretation of Results: Experiment 3  
Repeated treatment with the mGluR5 PAM CDPPB showed no evidence of an effect 
on spine density, spine head diameter, and spine length or spine volume. These results are 
surprising since mGluR5 PAMs are known to facilitate the induction of plasticity at 
hippocampal synapses (Ayala et al., 2009) and alter the expression of NMDA receptor 
subunits in the mPFC (Uslaner et al., 2009). However, these findings are consistent with 
published literature. Gass and colleagues (2014) showed that repeated administration of 
CDPPB at similar doses showed no evidenc of an effect on dendritic spine density or 
morphology in the mPFC after alcohol self-administration and forced abstinence. 
Alternatively, a separate group of rats underwent extinction training following alcohol 
self-administration, and in this group CDPPB produced an increase in dendritic spine 
density, maturity, and AMPA-mediated calcium currents, selectively in the infralimbic 
cortex. This suggests and interaction between CDPPB and engagement in behaviors 
known to invoke activity of the mPFC in order to produce discernible changes in spine 
density or morphology. Vanderklish and colleagues found that activation of Group I 
mGluRs increased spine length in hippocampal neurons in vitro (Vanderklish et al., 
2002). Behavioral studies offer contradictory findings, such that CDPPB has been shown 
to reverse induced cognitive impairments (Stefani & Moghaddam, 2010; Vales et al., 
2009), provide no evidence of effect on cognitive ability without a deficit (Darrah et al., 
2008), and show enhancement on spatial and recognition tasks in the absence of any 
impairment (Ayala et al., 2009; Balschun et al., 2006; Uslaner et al., 2009). Consistency 
with comparative literature is difficult to determine as few studies exist. The only other 
study to measure the effects of CDPPB on dendritic plasticity in the mPFC utilized 
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alcohol treatment and extinction/abstinence procedures (Gass et al., 2014). The addition 
of alcohol and extinction training may have had drastic effects on dendritic plasticity, as 
it is evident that spine number and shape are very responsive to pharmacological 
manipulation and learning (Brandon & Cross, 1982; Horner, 1993; Woolley et al., 1990). 
Our study strictly utilized repeated treatment of CDPPB and no other variables were 
incorporated. From the results of the current study and results from comparative 
literature, we can interpret that CDPPB may only exert pro-cognitive effects with the 
influence of either impairment/and or learning factors.  
Repeated administration of the mGluR5 NAM fenobam increased dendritic spine 
density in pyramidal neurons of the mPFC. Analysis of spine head diameters revealed 
that fenobam treatment produced an overall reduction in spine head diameter, and binned 
frequency analysis revealed that fenobam treatment increased the frequency of 
occurrence of spine head diameters <20 m, and decreased the frequency of occurrence 
of spine head diameters between 20 and 40 m, while leaving spine head diameters >40 
mm unaffected. To date no study has examined the effect of fenobam on structural 
plasticity, but we can speculate from published literature that examined similar 
mechanisms of action.  
Fenobam may increase spine density by acting as an antagonist on the mGluR5 
receptor, thus reducing mGluR5 activity. The reduction in mGluR5 activity may in turn 
cause reduced NMDAR activity, which is critical for normal synaptic function. 
Therefore, the increased spine density may be due to reduced neuronal signaling that may 
mediate cellular compensatory mechanisms in an effort to return stability to synaptic 
function. Dendritic spines are plastic and change rapidly as a function of behavior, 
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hormonal status, and synaptic activity (Brandon & Cross, 1982; Horner, 1993; Woolley 
et al., 1990). mGluR5 activation affects several postsynaptic scaffolding proteins (such as 
Homer, GKAP, and Shank) as well as intracellular signaling cascades including PKC and 
phosphoinositol signaling, all of which influence synaptic maturation and plasticity 
(Chen et al., 2012). Proper functioning of mGluR5 and NMDAR are essential for 
neuronal cytoarchitectural maturational processes, including dendritic morphology, 
axonal arborization (She et al., 2009; Wijetunge et al., 2008), and spine density (Datwani 
et al., 2002). Studies that support this notion include findings that mGluR5 knockout 
(KO) mice show significant increases in spine density in layer IV of the cerebral cortex 
(Chen et al., 2012), and deletion of NR1 subunit in NMDAR also produces an increase in 
spine density (Datwani et al., 2002). mGluR5 may indirectly regulate the synaptic 
plasticity mediated by NMDARs (Harney et al., 2006), as inhibition of mGluR5 leads to 
a reduction of NMDAR currents (Lu et al., 1997). The above studies are consistent with 
our findings, and overall it appears that decreased mGluR5 and/or NMDAR function 
causes increased spine density.  
Fenobam caused an increase in the frequency of spines with smaller terminal head 
point diameter and decreased the frequency of spines with medium terminal head point 
diameters. Spines with smaller terminal head point diameter may be caused by mGluR5-
mediated reduced NMDAR activity. Lack of excitatory function could increase the 
frequency of spines with smaller head size diameter as a result of cellular compensatory 
mechanisms. In an effort to maintain stable excitatory function, spinogenesis may occur 
to facilitate neurotransmission. Spine formation is often preceded by the development of 
filopodium-like or immature/thin spines, which are characterized as having small head 
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diameter (Dailey et al., 1996; Morest, 1969; Papa et al., 1995; Ramoa et al., 1987; 
Ulfhake & Cullheim, 1988). Filopodium-like spines have the potential to grow into 
mature spines and regulate synaptic function (Feng et al., 2002; Grutzendler et al., 2002; 
Parnass et al., 2000; Trachtenberg et al., 2002).  Intracellular proteins that physically link 
mGluR5 and NMDAR also influence spine morphology. As mentioned earlier, mGluR5 
and NMDAR are linked primarily by proteins such as Shank and Homer, but several 
other post synaptic proteins are involved as well. PSD-95 binding proteins link Shank to 
NDMAR (Boeckers et al., 1999; Naisbitt et al., 1999; Tu et al., 1999) and Homer binds to 
Shank, mGluR5 and IP3 (Naisbitt et al., 1999; Tu et al., 1999; Xiao et al., 2000). Through 
these connections, Shank can link NMDAR and mGluR5 (Sala et al., 2001).  Shank 
promotes the enlargement of spine heads via mechanisms that depend on the post 
synaptic recruitment and binding of Homer (Lim et al., 1999; Sala et al., 2001). Homer 
can promote spine enlargement by activating intracellular Ca
2+
 release in response to 
activation of mGluRs (Tu et al., 1998; Xiao et al., 1998).  Relevant to the current study, 
fenobam acts as an antagonist on mGluR5 receptors and indirectly reduces NMDAR 
activity, thereby reducing overall intracellular Ca
2+
 levels. This could lead to a disruption 
of mechanisms that would normally induce spine maturation, causing a higher frequency 
of immature spines. This conclusion is consistent with a study by Chen and colleagues 
(2012), which found mGluR5 KO mice to show significant increases in small spines in 
layer IV of the cerebral cortex, and is also consistent with the results of our study that 
fenobam increases the frequency of spines with smaller terminal head point diameter.   
Both fenobam and CDPPB revealed no significant difference on spine length or 
spine volume. This may be due to several factors, including short half-life of both drugs, 
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and/or the slower modulatory effects of PAMs and NAMs, as well as their allosteric 
mode of action. CDPPB has a half-life of 4 hrs in rats (Kinney et al., 2005), and fenobam 
has a half-life of 1 hr (Keck et al., 2013). Animals were treated once daily and thus 
subsequent studies may detect additional significant group differences by administering 
drugs more frequently.  
It should be noted that while CDPPB and fenobam are both PAMs and NAMs, 
respectively, they have different postsynaptic effects. CDPPB slowly facilitates mGluR5 
activity, while fenobam blocks all mGluR5 activity (Keck et al., 2013; Kinney et al., 
2005). The different effects on mGluR5 activity may explain why significant differences 
were observed between fenobam and vehicle, but not CDPPB and vehicle on spine 
density and spine head diameter. Additionally, spines are highly plastic and undergo 
continual actin-based motility on a time scale from seconds to minutes (Fisher et al., 
1998; Matus et al., 2000). Because of the dynamic nature of spine morphology, it may be 
that spines are able to rapidly adapt to drug-induced changes, ultimately resulting in 
fewer group differences.  
Thus, we hypothesize that blockade of mGluR5 may cause neuronal 
compensatory mechanisms in an effort to stabilize synaptic function, and that 
administration of mGluR5 PAMs may require either a pre-existing deficit or a learning 
component in order to have an effect on dendritic spine plasticity. However, since there 
are few other studies on the effects of mGluR5 PAMs and NAMs on dendritic spine 
density and morphology, future studies utilizing other doses, durations of treatment, and 
in animal models of neuropsychiatric diseases are clearly warranted before conclusions 
are made.  
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Significance of Findings: Experiment 3 
 Administration of CDPPB produced no evidence of effects on dendritic spine 
density, spine head diameter or spine length and volume. As mentioned above, it is 
possible that mGluR5 PAMs require a pre-existing deficit and/or the presence of a 
learning component in order to exert pro-cognitive effects or effects on dendritic spine 
plasticity. To our knowledge, the only other study that has examined the effects of 
mGluR5 PAMs on spine morphology was conducted by Gass and colleagues (2014), who 
showed that repeated administration of CDPPB following alcohol self-administration had 
no effect on dendritic spine plasticity in the mPFC in animals undergoing forced 
abstinence (consistent with the present results), and only exerted an effect when 
combined with extinction training procedures. Thus, future studies are warranted to 
determine the effects of CDPPB on dendritic spine plasticity in the mPFC when 
combined with other behavioral or cognitive tasks. 
 Our observed effects of fenobam on dendritic spine plasticity may be due to drug-
induced reductions in glutamatergic signaling that may induce cellular compensatory 
mechanisms in an effort to return stability to synaptic function. Dendritic spines are 
plastic and change rapidly as a function of behavior, hormonal status, and synaptic 
activity (Brandon & Cross, 1982; Horner, 1993; Woolley et al., 1990). Increases in the 
frequency of spines with smaller terminal head point diameter may be a result of indirect 
mGluR5 antagonist-induced NMDAR activity. That is, resulting fenobam-induced 
increases in the frequency of dendritic spines with small head diamaters may be a result 
of compensatory efforts by pyramidal neurons to overcome chronic mGluR5 and/or 
NMDAR inhibition. 
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This study adds the following novel and significant findings to the field: 1) repeated 
CDPPB treatment had no significant effect on dendritic spine morphology, possibly a 
result of the absence of a pre-existing neurochemical deficit and/or incorporation of a 
learning component that may be necessary to exert any changes in dendritic structure that 
may accompany pro-cognitive effects of mGluR5 PAMs, 2) repeated fenobam treatment 
produced a significant increase in dendritic spine density and reduced frequency of 
dendritic spines with small heads, findings that are consistent with those obtained from 
mGluR5 KO mice (Chen et al., 2012). 
 
Hypotheses Proved or Disproved: Experiment 1 
We hypothesized that mGluR5 PAMs would decrease pharmacologically induced 
cognitive impairments in a set-shifting task designed to assess perseverative responses as 
measured by percent correct after rule change. Our specific predictions were: MK-801 
administration will cause increased perseverative responses (decreased % correct) 
following task reversal, but MK-801 simultaneously administered with a cognitive 
enhancer such as CDPPB will reduce this effect. Also, CDPPB administered as a 
pretreatment to MK-801 will further reduce perseverative responses. 
Our findings support our hypothesis and predictions. Our results show that MK-
801 administration caused a significant increase in perseverative responses, as indicated 
by a decreased percent of correct responses following task reversal. Simultaneous 
administration of CDPPB and MK-801 partially reduced rates of perseverative responses, 
as indicated by slight increases in percent of correct responses as compared to rats treated 
with MK-801 alone. Lastly, administration of CDPPB as a pretreatment (30 min prior) to 
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MK-801 completely prevented perseverative responses, as indicated by a significant 
increase in percent correct responses, and no significant difference when compared to the 
vehicle administered group. 
 
Hypotheses Proved or Disproved: Experiment 2 
We hypothesized that mGluR5 PAMs would decrease MK-801 induced increases 
in extracellular glutamate levels in the mPFC. Our specific predictions were that MK-801 
administration will increase extracellular glutamate levels in the mPFC, and CDPPB 
pretreatment prior to MK-801 administration will reduce that effect. Also, we 
hypothesized that administration of CDPPB alone will cause a decrease in extracellular 
glutamate levels in the mPFC. Our hypotheses for effects of drug treatments on basal 
extracellular glutamate levels in the mPFC were as follows: CDPPB will increase basal 
glutamate levels, CDPPB/MK-801 will result in no significant differences on basal 
glutamate levels, and MK-801 will decrease basal glutamate levels.  
Our hypothesis was generally supported, but not all of our specific predictions 
were observed. As expected, MK-801 caused significant increases in extracellular 
glutamate levels in the mPFC, and pretreatment of CDPPB significantly reduced those 
effects. Surprisingly, chronic CDPPB treatment produced no significant effects on 
extracellular glutamate levels, which disproves the predicted hypothesis for this treatment 
group. Furthermore, our hypotheses on effects of drug treatment on basal glutamate 
levels were not supported for all treatment groups. 
The finding that CDPPB resulted in no significant difference on extracellular 
glutamate levels was not surprising since our hypothesis was based on the ability of 
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CDPPB to reverse MK-801 cognitive impairments in behavioral tasks. However, the lack 
of observed effects of CDPPB alone on extracellular glutamate levels was surprising 
since mGluR5 receptors are well known to modulate NMDA receptor activity. The most 
unexpected finding was the lack of significant difference in basal dialysate glutamate 
levels. We utilized a chronic ten day treatment regimen, and thus expected a difference in 
basal glutamate levels. Zuo and colleagues (2006) showed that repeated administration of 
MK-801 reduced extracellular glutamate levels in the mPFC, however they used a very 
high dose of MK-801 (0.6 mg/kg) compared to our dose (0.06 mg/kg). Thus, the 
currently utilized dose may be lower than that required to produce significant effects on 
basal extracellular glutamate levels. 
 
Hypotheses Proved or Disproved: Experiment 3 
We hypothesized that potentiation and inhibition of mGluR5 activity would 
produce opposing effects on dendritic spine density and morphology in the mPFC. 
Specifically, our predictions were that chronic administration of CDPPB will increase 
dendritic spine density and alter spine morphology (i.e., increase spine head diameter 
and/or volume) in the mPFC, while chronic administration of fenobam would decrease 
dendritic spine density and cause decreases in spine head diameter and spine volume in 
the mPFC. 
Surprisingly, chronic CDPPB treatment resulted in no significant differences in 
dendritic spine density or any of the spine morphology variables measured as compared 
to vehicle treated animals. However, chronic fenobam treatment resulted in increased 
dendritic spine density and produced an overall reduction in spine head diameters.   
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CDPPB and other mGluR5 PAMs have been well established in the published 
literature as a cognitive enhancer, and thus we hypothesized that CDPPB may exert its 
procognitive effects by increasing dendritic spine density and spine morphology. 
Fenobam, an mGluR5 NAM, was predicted to decrease dendritic spine density and spine 
morphology. This prediction was due to mGluR5 NAMs indirectly inhibiting NMDAR 
function, which we thought would have led to decreased synaptic function, and thus 
eventual spine atrophy/loss.   
 
Study Limitations 
 The current project has several limitations. Experiment 1 lacked a separate 
unimpaired control group that administered CDPPB alone (i.e., CDPPB/Vehicle). 
However, given that the purpose of CDPPB administration was to reverse MK-801 
induced set-shifting impairments, a CDPPB/vehicle treatment group was not included. 
We can speculate that CDPPB/vehicle treated animals would have performed no different 
than vehicle/vehicle treated animals, as several studies have shown CDPPB treatment 
alone to provide no evidence of effects. Darrah and colleagues (2008) showed that 
CDPPB treatment resulted in no significant differences when compared to vehicle 
treatment in an operant-based cognitive flexibility task, similar to our study. Additionally, 
this study measured the effects of mGluR5 NAM in the same task, and also found no 
significant differences when compared to vehicle. A second study also reports CDPPB to 
show no evidence of effect on cognitive set-shifting alone, and in fact reported that 
animals treated with CDPPB alone needed more time to finish trials (Stefani & 
Moghaddam, 2010). Our two other studies also showed CDPPB treatment alone to have 
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no significant effect on either extracellular glutamate levels or spine density/morphology 
in the mPFC. Thus, it is plausible that cognitive or other types of deficits are necessary in 
order for mGluR5 PAMs to produce observable effects on parameters such as 
extracellular glutamate concentrations. However, in unimpaired animals, mGluR5 PAMs 
have been shown to have improved spatial and recognition memory abilities (Ayala et al., 
2009; Balschun et al., 2006; Uslaner et al., 2009) Therefore, addition of a CDPPB/vehicle 
group may have provided further interesting results to this study, as well as guiding 
future research directions.  
 Experiment 2 utilized in vivo microdialysis procedures to measure the effects of 
CDPPB and MK-801 on extracellular glutamate levels in the mPFC. Microdiaylsis is a 
time consuming and difficult procedure that frequently is hindered by chronic treatment 
regimens, troubleshooting of the neurochemical assay, and probe patency issues. Thus, 
our sample sizes (6-8/group) are not as high as would be optimal for these studies. 
Adding to the difficulty of this procedure, microdialysis typically measures glutamate 
from multiple sources, both neurons and glia, and currently it was not possible to 
determine the source(s) of extracellular glutamate detected by microdialysis procedures 
(Timmerman & Westerink, 1997). Also, we found no treatment effect on basal levels of 
extracellular glutamate, which was surprising due to the chronic treatment regimen and 
known effects of MK-801 on extracellular glutamate in the mPFC. Animals were treated 
once daily, thus it may be possible that due to the short half-life of CDPPB (4 hrs) and 
MK-801 (2 hrs) (Kinney et al., 2005; Vezzani et al., 1989) treatments may have already 
cleared the system upon the morning of sample collection. Therefore, a twice daily 
  110 
treatment regimen may have resulted in significant treatment differences in basal 
extracellular glutamate levels.  
 Experiment 3 assessed the effects of both an mGluR5 PAM and NAM on 
dendritic spine density and spine morphology. This study was by far the most labor-
intensive and time consuming. Because of this, the sample sizes of our treatment groups 
were limited. We chose to assess the effects of mGluR5 modulation on dendritic 
plasticity to first determine any significant effects, and if so, add additional treatment 
groups such as MK-801 alone and CDPPB/MK-801. Unfortunately, this was not possible 
within a reasonable time frame, and thus the interpretations of our findings are limited to 
how mGluR5 PAMs or NAMs affects dendritic spine plasticity, which may underlie their 
effects on cognitive functions. Without these additional groups, we can only speculate as 
to the effects of mGluR5 PAMs or NAMs on dendritic spine plasticity and how these 
effects are relevant to schizophrenia-related cognitive impairments. Also, the short half-
life of CDPPB (4 hrs.) and fenobam (1 hr.) may have affected the significance of our 
results (Kinney et al., 2005; Keck et al., 2013). These short half-lives indicate that despite 
ten daily treatments, the effects observed may be more representative of acute 
administration, rather than our intentions of chronic administration. A twice daily 
treatment regimen could more adequately model the effects of chronic treatment.  
 
Suggested Directions for Future Research 
 In regards to the lack of effects of CDPPB alone on extracellular glutamate levels 
and dendritic spine density and morphology, it is possible that CDPPB may only exert 
effects in the presence of either an impairment and/or learning/environmental change. 
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Gass and colleagues (2014) offer support for this suggestion, demonstrating that animals 
treated with CDPPB only showed increased dendritic spine density and increased spine 
head diameter in the mPFC when they underwent extinction training following alcohol 
self-administration, but not when they underwent forced abstinence in their home cage. 
Additionally, three behavioral studies showed that CDPPB can have cognitive enhancing 
effects without prior induction of a cognitive impairment (Ayala et al., 2009; Balschun et 
al., 2006; Uslaner et al., 2009). Alternatively, Darrah and colleagues (2008) showed 
CDPPB to provide no evidence of effect on cognition in the presence of a 
learning/memory component, and in the absence of an induced deficit. Due to these 
contradicting findings in the literature, future studies on effects of mGluR5 PAMs on 
extracellular glutamate and dendritic structural plasticity should employ different 
treatment doses and regimens, as well as inducing a deficit prior to CDPPB 
administration. In addition, investigating the effects of CDPPB in combination with a 
learning component in the experimental design, are necessary to further clarify potential 
mGluR5 PAM cognitive enhancing effects.  
Results from our second study showed that MK-801 increases extracellular glutamate 
in the mPFC, and that CDPPB is able to reverse that effect. Currently the exact 
neurochemical circuits and signaling mechanisms that underlie these effects are 
unknown. From previously published literature, we can interpret that the effects of these 
ligands are not likely mediated by presynaptic localized mGluR5 and NMDAR, as they 
are predominantly localized to postsynaptic membranes on dendritic spines (Gass & 
Olive, 2008; Niswender & Conn, 2010; Romano et al., 1995).  Alternatively, some 
investigators have reported evidence of small populations of cortical neurons expressing 
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these receptors on presynaptic terminals (Corlew et al., 2008; Duguid, 2013; Romano et 
al., 1995). Taken together, it is more likely that both CDPPB and MK-801 act on multi-
synaptic feedback mechanisms, which regulate local glutamate levels in the mPFC. 
However, this is speculation, and thus further research is necessary to clarify and confirm 
the precise mechanisms for the effects of both CDPPB and MK-801. 
 
Clinical Applicability 
Current antipsychotics are not effective for the treatment of schizophrenia cognitive 
impairments. These studies provide clinical applicability by means of drug discovery that 
is focused on testing novel compounds to reduce the cognitive impairments of 
schizophrenia. mGluR5 PAMs appear to be an effective mechanism for the treatment of 
cognitive impairments associated with schizophrenia, as shown by studies utilizing 
animal models of schizophrenia thus far. Experiment 1 offers high translational value, as 
the task is PFC-dependent and employs a high working memory load. Also, we utilized 
chronic drug administration to more closely resemble daily intake patterns that are 
generally required for therapeutic purposes in humans. Thus, the attributes of this study 
more adequately measure behaviors observed in cognitive impairments (i.e., 
perseverative responses) in people with schizophrenia, and also reflect a treatment 
regimen that would most likely be utilized in humans. Adding to the clinical relevance of 
our results is the type of schizophrenia model used. Disruption in excitatory transmission 
in the mPFC is a leading hypothesis for the pathophysiology of schizophrenia, which may 
underlie the cognitive impairments observed in these patients. Results from our studies, 
and those of others, show that NMDAR antagonists and mGluR5 NAMs dysregulate both 
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excitatory transmission and dendritic plasticity in the mPFC. Furthermore, our findings 
that mGluR5 PAMs reduce the effects of NMDAR antagonists support the clinical 
applicability of these novel compounds as possible treatments for the cognitive deficits in 
people with schizophrenia.  
 
Culmination of Experimental Findings 
 Administration of the mGluR5 PAM CDPPB resulted in a reversal of cognitive 
impairments in an animal model of schizophrenia, as observed by a lack of perseverative 
responses in a cognitive set-shifting task. To identify a possible neurochemical correlate 
of the ability of CDPPB to reverse cognitive impairments, the effects of CDPPB on 
extracellular glutamate levels in the mPFC were measured via in vivo microdialysis, as 
were the effects of this compound on dendritic spine density and morphology in this 
region. Cognitive impairments associated with schizophrenia may stem from 
dysfunctional glutamatergic circuitries that ultimately result in reduced PFC function 
(Olney & Farber, 1995; Olney et al., 1999). NMDAR antagonists such as MK-801 and 
PCP are excellent animal models for the symptoms of schizophrenia (Jones et al., 2011), 
and MK-801 has been shown to significantly elevate extracellular glutamate levels 
(Adams & Moghaddam, 2001; Lena et al., 2006; Lopez-Gil et al., 2007, Lopez-Gil et al., 
2009; Lorrain et al., 2003; Moghaddam et al., 1997; Pietraszek et al., 2009; Roenker et 
al., 2011; Roenker et al., 2012; Zuo et al., 2006). In order to better understand possible 
mechanisms underlying the ability of CDPPB to reverse MK-801 induced cognitive 
impairments in behavioral tasks, it was necessary to identify whether CDPPB could also 
reverse the effects of MK-801 on extracellular glutamate levels in the mPFC in in vivo 
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microdialysis. Administration of CDPPB prior to MK-801 resulted in normalized 
extracellular glutamate levels in the mPFC, and while these findings are currently only a 
neurochemical correlate of MK-801 induced cognitive impairments, it is tempting to 
speculate that CDPPB may exert cognitive enhancing effects by reversing 
hyperglutamatergic singaling that results from MK-801 administration. Surprisingly, 
administration of CDPPB alone showed no evidence of effects on extracellular glutamate 
levels.  
 To further elucidate possible mechansims involved in the pro-cognitive effects of 
CDPPB, the effects of an mGluR5 PAM and NAM on dendritic spine density and spine 
head diameter were examined. Dendritic spine density and spine head size are generally 
correlated with synaptic function. During LTP induction enlargement of spine heads are 
observed, and during LTD induction smaller spine heads are observed (Kasai et al., 
2010). Patients with schizophrenia have observed spine atrophy and loss of dendritic 
spine density in the DLPFC, as well as decreased neuronal activity during cognitive 
tasks, as shown by imaging studies (Glantz & Lewis, 2000; Hirsch et al., 1997; Tan et al., 
2007). Since cognitive impairments associated with schizophrenia may be due to loss of 
neuronal plasticity we hypothesized that CDPPB would cause increased spine density and 
spine head diameter in the mPFC. Surprisingly, CDPPB showed no evidence of 
significant effects on dendritic spine density or spine head size in the mPFC. However, 
the mGluR5 NAM fenobam caused significant increases in dendritic spine density as well 
as the frequency of spines with smaller head size diameter. These findings demonstrate 
the need for additional studies on the effects of mGluR5 PAMs on dendritic spine density 
and morphology as possible neurostructural correlates and mechanisms of the cognition 
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enhancing effects of these compounds. For example, Gass and colleagues (2014) have 
shown that CDPPB only increased dendritic spine density and spine head size when 
testing conditions included a learning component (Gass et al., 2014). Taking this finding 
into account, and the lack of evidence of effects from administration of CDPPB alone on 
extracellular glutamate levels in experiment 2, it is reasonable to speculate that in order 
for CDPPB to exert pro-cognitive effects experimental conditons may need to include 
either a pre-existing deficit, incorporate a learning component into the testing paradigm, 
or both. It is also possible that the effects of CDPPB may occur by simply blocking the 
acitivity of MK-801 on the receptor and not via mechanism of learning or plasticity. Due 
to findings from Gass and collagues (2014) and behavioral studies showing that CDPPB 
is able to enhance cognition in the absence of a deficit, but in the presence of learning 
(Ayala et al., 2009; Balschun et al., 2006; Uslaner et al., 2009; Xu et al., 2013), it is more 
likely that CDPPB may only enhance cognition when the organism is in a compromised 
state or when the mPFC circuitries are engaged. Thus, the culmination of results from our 
studies suggest that potentiation of mGluR5 function is a viable approach for cognitive 
enhancement, particularly in models of schizophrenia, but that further investigation of the 
exact mechanisms of effects of mGluR5 PAMs is necessary to make more clear 
conclusions.   
 
Final Conclusions 
The findings of these studies are important as they propose an alternative 
approach to current treatments for schizophrenia, which are currently unable to relieve 
the cognitive impairments associated with schizophrenia, and have several adverse side 
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effects. Our work underscores the importance of assessing novel compounds in 
paradigms that more adequately measure the cognitive deficits of schizophrenia, and 
utilize treatment regimens reflective of human daily intake. Additionally, this work 
illustrates the importance of tying together the effects of novel compounds on several 
aspects including behavior, neurochemistry and neuronal structure in an effort to better 
interpret and predict drug efficacy. Based on our findings that CDPPB is effective in 
reducing impairments in cognition and disrupted neurotransmission in rodent models of 
schizophrenia, we believe that mGluR5 PAMs may be a novel mechanism for the 
treatment of cognitive impairments in schizophrenia. Finally, further characterization of 
mGluR5 and NMDAR interactions may provide valuable insight into the causes of 
cognitive deficits in patients with schizophrenia. This work will hopefully aid in the 
development of more efficacious treatments, and offer patients with schizophrenia the 
opportunity to lead fulfilling lives with alleviation of symptoms in all clinical domains 
(positive, negative, and cognitive). 
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Figure 1A: Performance in DMS/DNMS test for all 4 treatment groups: vehicle/vehicle 
(n=9), vehicle/MK-801 (n=6), CDPPB/MK-801 (n=7), and CDPPB 30 min/MK-801 
(n=9). *indicates p<0.05 on days 29-35, 37, 39-41 between groups vehicle/vehicle vs. 
vehicle/MK-801. 
 
  166 
 
 
 
 
 
 
 
 
 
 
 
 
 
22 24 26 28 30 32 34 36 38 40 42
0.00
0.25
0.50
0.75
1.00
Vehicle/Vehicle
Vehicle/MK-801
*** * *
*
*
*
*
**
Day
%
 C
o
rr
ec
t 
R
es
p
o
n
d
in
g
 /
 1
0
0
 
 
Figure 1B: Re-plotted from figure 1A. Performance in DMS/DNMS test between group 
vehicle/vehicle and vehicle/MK-801. Administration of MK-801 (0.06 mg/kg) produces a 
significant deficit in ability to set-shift. *indicates p<0.05 on days 29-35, 37, 39-41. 
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Figure 1C: Re-plotted from figure 1A. Performance in DMS/DNMS test between group 
CDPPB 30 min/MK-801 and vehicle/MK-801. Administration of MK-801 (0.06 mg/kg) 
produces a significant deficit in ability to set-shift, which pretreatment with CDPPB (20 
mg/kg) reverses. *indicates p<0.05 on days 29-35, 37, 39-41. 
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Figure 1D: Re-plotted from figure 1A. No differences in DMS/DNMS performance in 
unimpaired (vehicle/vehicle) animals and those receiving CDPPB (20 mg/kg) 30 min 
prior to MK-801 (0.06 mg/kg), (p>0.05). 
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Figure 1E: Re-plotted from figure 1A. Performance in DMS/DNMS test between group 
CDPPB/MK-801 and vehicle/MK-801. Deficits in set-shifting were alleviated slightly by 
co-administration of CDPPB (20 mg/kg)/MK-801 (0.06 mg/kg). *indicates p<0.05 on 
day 33, with trends on days 31, 34 and 37 (p=0.08, 0.07, and 0.06). 
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Figure 1F: Performance in DMS/DNMS test between 3 treatment groups CDPPB 30 
min/MK-801, vehicle/vehicle, and vehicle/MK-801. No differences in performance in 
acquiring task reversal when treatments were administered post task-shift (p>0.05). 
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Figure 2A: The gray shaded area represents the area of mPFC where microdialysis 
probes (2 mm membrane length) were placed in the present study. Drawing adapted from 
Paxinos & Watson, 2007. 
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Figure 2B) Effects of chronic administration of CDPPB and/or MK-801 on extracellular 
glutamate levels in the mPFC. Data points represent mean values within each treatment 
group and are expressed as percent change from average glutamate levels obtained during 
collection of four baseline pre-injection samples (30 min each). Error bars are omitted for 
clarity of data presentation. The first injection (vehicle or CDPPB) was given at arrow 1, 
followed 30 min later by the second injection, arrow 2 (saline or MK-801). 
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Figure 2C) Effects of chronic administration of CDPPB and/or MK-801 on extracellular 
glutamate levels in the mPFC. AUC values (based on raw dialysate glutamate content) 
for pre-injection baseline samples 1-4. Data are presented as mean±SEM, and show no 
significant group difference (p>0.05). 
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Figure 2D) Effects of chronic administration of CDPPB and/or MK-801 on extracellular 
glutamate levels in the mPFC. AUC values (based on raw dialysate glutamate content) 
for post-injection baseline samples 5-9. Data are presented as mean±SEM. * indicates 
p<0.05 between the specified treatment groups. n.s. = not significant. 
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Figure 3A) Location of labeled neurons in the mPFC that were analyzed in the present 
study. Neurons were chosen for confocal imaging and spine analysis if they were located 
in the prelimibic (PL) and or infralimbic (ILA) regions.  Figure adapted from Swanson 
(1999).    
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Figure 3B) Representative pyramidal neuron with traced apical dendritic segment and 
spines (boxed inset).
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Figure 3C) Compared to vehicle, spine density was increased by fenobam but not by 
CDPPB (***p<0.001 vs. vehicle). 3D) Compared to vehicle treated animals, fenobam 
increased the frequency of smaller spine head diameter. Inset: overall spine head 
diameter was significantly decreased in rats treated with fenobam compared to vehicle 
treated rats (*p<0.05).  
 
